register_number stringlengths 11 11 | secondary_id listlengths 1 10 | url stringlengths 44 44 | brief_title stringlengths 20 290 | brief_summary stringlengths 63 5.05k | official_title stringlengths 25 483 ⌀ | intervention listlengths 1 19 | arm_intervention listlengths 1 21 ⌀ | f_condition listlengths 1 135 | sponsor listlengths 1 1 | collaborator listlengths 1 25 | experimental_drug listlengths 1 13 | study_identifier listlengths 1 7 ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT00667901 | [
{
"id_field": "org_study_id",
"id_value": [
"CDR0000592958"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"P30CA072720"
]
},
{
"id_field": "secondary_id",
"id_value": [
"CINJ-090603"
]
},
{
"id_field":... | https://clinicaltrials.gov/study/NCT00667901 | Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery | RATIONALE: Riluzole may stop or slow the growth of tumor cells and may be an effective treatment for melanoma.<br/>PURPOSE: This early phase I trial is studying how well riluzole works in treating patients with stage III or stage IV melanoma that can be removed by surgery. | A Phase 0 Trial of Riluzole in Patients With Resectable Stage III and IV Melanoma | [
{
"name": "riluzole",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name": "protein expression analysis",
"normalized_type": "288887f0545745558ff1ab1c85757552",
"type": "Genetic"
},
{
"name": "reverse transcripta... | null | [
"Melanoma (Skin)"
] | [
"University of Medicine & Dentistry of New Jersey"
] | [
"National Cancer Institute"
] | [
[
{
"name": "利鲁唑",
"lang": "CN"
},
{
"name": "Riluzole",
"lang": "EN"
},
{
"name": "リルゾール",
"lang": "JP"
}
]
] | null |
NCT02937844 | [
{
"id_field": "org_study_id",
"id_value": [
"SBNK-2016-016-01"
]
}
] | https://clinicaltrials.gov/study/NCT02937844 | Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme | CAR T cell immunotherapy has achieved great success in CD19+ B-cell malignancies. Whether this new generation of cell-based immunotherapy can be applied to solid tumors remain to be investigated, partly due to hostile immune-suppressive tumor microenvironment which favors tumor growth but not immune system. Signaling p... | A Safety and Efficacy Study of Autologous Chimeric Switch Receptor Engineered T Cells Redirected to PD-L1 in Patients With Recurrent Glioblastoma Multiforme | [
{
"description": "Prescribed CSR T cells are infused intravenously to patients in a three-day split-dose regimen（day0,10%; day1, 30%; day2, 60%）.",
"name": "Anti-PD-L1 CSR T cells",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "250 mg/m^2, d... | [
{
"design_group_description": "Patients will receive lymphodepletion chemotherapy consisting of fludarabine and cyclophosphamide, followed by intravenous infusion of autologous anti- PD-L1 CSR T cells. A standard 3+3 escalation approach will be used to obtain the safe dosage of CAR T cells. The tested CAR T cel... | [
"Glioblastoma Multiforme"
] | [
"Beijing Sanbo Brain Hospital Co., Ltd."
] | [
"Beijing Mali Biotechnology Co Ltd"
] | [
[
{
"name": "Anti-PDL1 chimeric switch receptor modified T-cell therapy (Marino Biotechnology)",
"lang": "EN"
}
],
[
{
"name": "磷酸氟达拉滨",
"lang": "CN"
},
{
"name": "Fludarabine Phosphate",
"lang": "EN"
},
{
"name": "フルダラビンリン酸エステル",
"lang... | null |
NCT06716905 | [
{
"id_field": "org_study_id",
"id_value": [
"ACT500-4/01"
]
},
{
"id_field": "secondary_id",
"id_value": [
"ACT500-4/01"
]
}
] | https://clinicaltrials.gov/study/NCT06716905 | Safety, Tolerability, and Pharmacokinetics of ACT500 in Healthy Adult Participants | This is a single-center, randomized, double-blind, placebo-controlled Phase I clinical study, divided into two parts. The first part is a single-dose escalation study (Part1,SAD study phase), and the second part is a multiple-dose escalation study (Part2,MAD study phase). It's aimed to evaluate the safety, tolerability... | A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Dose Escalations of ACT500 (Formerly Known as NM6606) in Chinese Healthy Adult Participants | [
{
"description": "Participants will receive a single ascending oral dose of ACT500 Tablets under fasting state on the first day in Part 1",
"name": "ACT500 tablets",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Participants will receive placebo m... | [
{
"design_group_title": "Part 1:ACT500 Tablets",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Participants will receive a single ascending oral dose of ACT500 Tablets under f... | [
"Non-alcoholic Steatohepatitis"
] | [
"Xiamen Amoytop Biotech Co. Ltd."
] | [
"Zhongnan hospital of wuhan university"
] | [
[
{
"name": "NM-6606",
"lang": "EN"
}
]
] | null |
NCT02960646 | [
{
"id_field": "org_study_id",
"id_value": [
"2014-0738"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2016-01915"
]
},
{
"id_domain": "M D Anderson Cancer Center"... | https://clinicaltrials.gov/study/NCT02960646 | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | This pilot phase I trial studies the side effects of engineered donor stem cell transplant in treating patients with hematologic malignancies. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft-versus-host disease). Using T cells specially selected fr... | Phase I Clinical Trial Using an Engineered Peripheral Blood Graft for Haploidentical Transplantation | [
{
"description": "Given IV",
"name": "Cyclophosphamide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"(-)-Cyclophosphamide",
"2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate",
"CP monohydrate",
"CTX",
"C... | [
{
"design_group_description": "Patients receive melphalan IV over 30 minutes on day -6 and fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo TBI on day -2 and CD45RA depleted peripheral blood stem cell transplantation on day 0. Patients also receive cyclophosphamide IV over 3 hours on days... | [
"Acute Lymphoblastic Leukemia",
"Acute Myeloid Leukemia",
"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome",
"Aplastic Anemia",
"Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
"Chronic Myelomonocytic Leukemia",
"Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Po... | [
"The University of Texas MD Anderson Cancer Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "磷酸氟达拉滨",
"lang": "CN"
},
{
"name": "Fludarabine Phosphate",
"lang": "EN"
},
{
"name": "フルダラビンリン酸エステル",
"lang": "JP"
}
],
[
{
"name": "环磷酰胺",
"lang": "CN"
},
{
"name": "Cyclophosphamide",
"lang": "EN"
... | null |
NCT04673630 | [
{
"id_field": "org_study_id",
"id_value": [
"D5180C00025"
]
},
{
"id_field": "acronym",
"id_value": [
"TRAILHEAD"
]
}
] | https://clinicaltrials.gov/study/NCT04673630 | Study to Evaluate the Pharmacokinetics of Tezepelumab in Children With Asthma | This study will evaluate the pharmacokinetic (PK) profile of a single subcutaneous (SC) dose of tezepelumab in children aged ≥ 5 to 11 years with asthma. | A Phase I, Open-label Study to Evaluate the Pharmacokinetics of Tezepelumab in Children ≥ 5 to 11 Years of Age With Mild, Moderate, or Severe Asthma (TRAILHEAD) | [
{
"description": "Single dose subcutaneous injection",
"name": "Tezepelumab",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
}
] | [
{
"design_group_description": "Tezepelumab subcutaneous injection",
"design_group_title": "Tezepelumab",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Single dose subcutan... | [
"Asthma"
] | [
"AstraZeneca PLC"
] | [
"Amgen, Inc."
] | [
[
{
"name": "特泽利尤单抗",
"lang": "CN"
},
{
"name": "Tezepelumab",
"lang": "EN"
},
{
"name": "テゼペルマブ (遺伝子組換え)",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "49a4355543e205d5224a42a45ae8e902",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "59230d8858e40059de4a28ead5900900",
"s... |
NCT01076868 | [
{
"id_field": "org_study_id",
"id_value": [
"SMRU0909"
]
},
{
"id_field": "acronym",
"id_value": [
"VHC"
]
}
] | https://clinicaltrials.gov/study/NCT01076868 | Incidence of Vivax Along the Thai Burma Border | This is a continuous cohort study consisting of 200 participants (one third 6 months old to 5 years, one third 6 to 15 years old, one third ≥ 15 years old) i.e. a new patient will be recruited (from the same age group) for any patient who develops a Pv infection so that the cohort will always have 200 patients for 3 ye... | Determining the Incidence of New Plasmodium Vivax Infections After Radical Treatment Following Vivax Malaria Along the Thai Burma Border | [
{
"description": "Primaquine x 14 days",
"name": "Primaquine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"primaquine 0.5 mg/kg/day"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Primaquine 14 days",
"design_group_title": "Primaquine",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Primaquine x 14 days",
"inter... | [
"Vivax Malaria"
] | [
"University of Oxford"
] | [
"Mahidol University"
] | [
[
{
"name": "磷酸伯氨喹",
"lang": "CN"
},
{
"name": "Primaquine Phosphate",
"lang": "EN"
},
{
"name": "プリマキンリン酸塩",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "VHC"
}
] |
NCT06732427 | [
{
"id_field": "org_study_id",
"id_value": [
"2024-YCRF-M1021"
]
}
] | https://clinicaltrials.gov/study/NCT06732427 | Clinical Study of Fospropofol Disodium for Injection in the Painless Endoscopic Diagnosis and Treatment | This is a study on the efficacy and safety of fospropofol disodium for injection in painless endoscopic diagnosis and treatment, project No.2024-YCRF-M1021, which will take more than 2 years to complete.<br/>This is a multicenter, randomized, double-blind, controlled clinical study. Using a computer-generated randomize... | Efficacy and Safety of Fospropofol Disodium for Injection in the Painless Endoscopic Diagnosis and Treatment: a Multicenter-prospective, Randomized, Controlled Trial | [
{
"description": "Group L received slow intravenous sufentanyl 0. 1 ug / kg +fospropofol Disodium for injection 8mg / kg (completed within 60 seconds)",
"name": "fospropofol Disodium for injection",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"sulfentanyl"
],
... | [
{
"design_group_description": "Painless gastrointestinal endoscopy in group L was mainly performed using fospropofol Disodium for injection",
"design_group_title": "Fospropofol Disodium",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
... | [
"Efficacy and Safety"
] | [
"Affiliated Hospital of Nantong University"
] | [
"Rugao People's Hospital"
] | [
[
{
"name": "磷丙泊酚二钠",
"lang": "CN"
},
{
"name": "Fospropofol Disodium",
"lang": "EN"
}
]
] | null |
NCT06060587 | [
{
"id_field": "org_study_id",
"id_value": [
"NU 23U08"
]
},
{
"id_domain": "CTRP",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2023-07135"
]
},
{
"id_domain": "Northwestern IRB",
"id_field": "secondary_id",
"id_type... | https://clinicaltrials.gov/study/NCT06060587 | Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone | This is a phase II, randomized, open label study comparing first line therapy with AThis is a phase II, randomized, open label study comparing first line therapy with ADT + abiraterone (doublet arm) or ADT + abiraterone + docetaxel (triplet arm) in low volume, metastatic hormone sensitive prostate cancer (mHSPC).<br/>T... | A Randomized Phase II Study of ADT + Abiraterone Versus ADT + Docetaxel + Abiraterone in Patients With Low Volume Metastatic Hormone Sensitive Prostate Cancer | [
{
"description": "75 mg/m2 via IV",
"name": "Docetaxel",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Prior to randomization as part of standard of care.",
"name": "ADT",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": ... | [
{
"design_group_description": "Abiraterone+Docetaxel+ADT<br/>Abiraterone Abiraterone acetate will be four (250 mg) tablets (total dose/day 1000 mg). Abiraterone administration is per a 12-week cycle.<br/>Abiraterone must be taken with prednisone. Prednisone will be provided as 5 mg tablets.<br/>Docetaxel Doceta... | [
"Prostate Cancer"
] | [
"Northwestern University"
] | [
"National Cancer Institute"
] | [
[
{
"name": "醋酸阿比特龙",
"lang": "CN"
},
{
"name": "Abiraterone acetate",
"lang": "EN"
},
{
"name": "アビラテロン酢酸エステル",
"lang": "JP"
}
],
[
{
"name": "多西他赛",
"lang": "CN"
},
{
"name": "Docetaxel",
"lang": "EN"
},
{
... | null |
NCT01474395 | [
{
"id_field": "org_study_id",
"id_value": [
"1115-00"
]
}
] | https://clinicaltrials.gov/study/NCT01474395 | N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia | Persistent neurocognitive deficits are a major cause of severe disability and impaired long-term psychosocial outcome in schizophrenia (SZ). In particular, within the auditory system, early deficits such as the behavioral and neurophysiological ability to match tones that vary in pitch correlate with impairments in aud... | NMDA and Cognitive Remediation in Schizophrenia | [
{
"description": "Subjects will then undergo three treatment visits. Each visit will begin with a pre treatment MMN/visual motion paradigm. Subjects will then receive DSR (60 mg/kg) or placebo and begin a one-hour SBR intervention. SBR will begin approximately 30 minutes after drug administration, to coincide w... | [
{
"design_group_description": "double blind dose of d-serine",
"design_group_title": "D-serine 60 mg/kg",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Every subject will ... | [
"Schizophrenia",
"Schizoaffective Disorder"
] | [
"Nathan S. Kline Institute for Psychiatric Research"
] | [
"Columbia University"
] | [
[
{
"name": "D-Serine",
"lang": "EN"
}
]
] | null |
NCT02252523 | [
{
"id_field": "org_study_id",
"id_value": [
"CHU-210"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2013-004697-10"
]
}
] | https://clinicaltrials.gov/study/NCT02252523 | Dexmedetomidine-based Sedation in Neurocritical Care Patients | This will be an open, prospective pilot study with pharmacological analysis. This study is designed to assess the efficacity and safety of dexmedetomidine-based sedation in two subgroups of neurocritically ill patients requiring mechanical ventilation for more than 48 hours. Those with or at risk for intracranial hyper... | Feasibility of Dexmedetomidine-based Sedation in Neurocritical Care Patients : a Pilot Study | [
{
"name": "Dexmedetomidine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_title": "DEXMEDETOMIDINE",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_name": "Dexmedetomidine",
"intervention_type": "Drug",
"normalized_intervention_type"... | [
"Acute Brain Injuries"
] | [
"Centre Hospitalier Universitaire de Clermont Ferrand"
] | [
"Orion Oyj"
] | [
[
{
"name": "盐酸右美托咪定",
"lang": "CN"
},
{
"name": "Dexmedetomidine Hydrochloride",
"lang": "EN"
},
{
"name": "デクスメデトミジン塩酸塩",
"lang": "JP"
}
]
] | null |
NCT05406479 | [
{
"id_field": "org_study_id",
"id_value": [
"BE-PEOPLE Phase 2"
]
},
{
"id_field": "acronym",
"id_value": [
"BE-PEOPLE P2"
]
}
] | https://clinicaltrials.gov/study/NCT05406479 | Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy (Phase 2) | This study will evaluate a combination of bedaquiline and rifampicin as post exposure prophylaxis (PEP) for leprosy in Comoros. It will be a follow-up to the PEOPLE trial on PEP with rifampicin, which is ending in 2022. This new trial will be called the 'Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy' or 'B... | Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy: Phase 2 Study | [
{
"description": "Single dose of Bedaquiline",
"name": "BE-PEP (Bedaquiline)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Single dose of Rifampicin",
"name": "SDR-PEP",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": ... | [
{
"design_group_description": "Eligible participants will receive one dose of Bedaquiline plus Rifampicin",
"design_group_title": "BE-PEP (Bedaquiline Post-Exposure Prophylaxis)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"interve... | [
"Leprosy"
] | [
"Instituut voor Tropische Geneeskunde"
] | [
"Damien Foundation"
] | [
[
{
"name": "富马酸贝达喹啉",
"lang": "CN"
},
{
"name": "Bedaquiline Fumarate",
"lang": "EN"
},
{
"name": "ベダキリンフマル酸塩",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "854e0423d39a52ad532e2285a2235e2e",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "BE-PEOPLE P2"
}
] |
NCT00452075 | [
{
"id_field": "org_study_id",
"id_value": [
"ML 20539"
]
}
] | https://clinicaltrials.gov/study/NCT00452075 | Erlotinib as First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) for Patients Unfit for Chemotherapy | A phase II study of Tarceva (Erlotinib) and predictive markers as first-line treatment of advanced non-small cell lung cancer for patients unfit for chemotherapy (NSCLC) Clinical Phase II Stage IIIB or IV non-small cell lung cancer (NSCLC) Primary end point: Disease control rate (= CR+PR and SD at 8 weeks /patients). S... | A Phase II Study of Erlotinib and Predictive Markers as First-line Treatment of Advanced Non-small Cell Lung Cancer for Patients Unfit for Chemotherapy | [
{
"description": "150mg daily",
"name": "erlotinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"tarceva"
],
"type": "Drug"
}
] | [
{
"design_group_description": "erlotinib daily",
"design_group_title": "arm 1 medicine",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "150mg daily",
"intervention_... | [
"Non Small Cell Lung Cancer"
] | [
"Rigshospitalet"
] | [
"Hoffmann-La Roche, Inc."
] | [
[
{
"name": "盐酸厄洛替尼",
"lang": "CN"
},
{
"name": "Erlotinib Hydrochloride",
"lang": "EN"
},
{
"name": "エルロチニブ塩酸塩",
"lang": "JP"
}
]
] | null |
NCT02695628 | [
{
"id_field": "org_study_id",
"id_value": [
"IRB-29768"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2016-00041"
]
},
{
"id_domain": "OnCore",
"id_field": "s... | https://clinicaltrials.gov/study/NCT02695628 | [18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer | This clinical trial studies how well 18F-fluoromisonidazole ([18F]FMISO) positron emission tomography (PET)/computed tomography (CT) works after transcatheter arterial embolization in imaging tumors in patients with liver cancer. Transcatheter arterial embolization blocks blood flow to tumor cells by inserting tiny for... | Assessment of Treatment-Induced Tissue Hypoxia After Transcatheter Arterial Embolization of Hepatocellular Carcinoma: A Feasibility Study With [18F]FMISO PET/CT | [
{
"description": "Undergo [18F] FMISO PET/CT",
"name": "18F-Fluoromisonidazole",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"18F-MISO",
"18F-Misonidazole",
"FMISO"
],
"type": "Drug"
},
{
"description": "Undergo transcatheter arterial embo... | [
{
"design_group_description": "Patients undergo transcatheter arterial embolization. Patients also receive 18F-fluoromisonidazole IV and undergo PET/CT scans 4 weeks prior to embolization treatment and in the 20 hours following completion of treatment.",
"design_group_title": "Diagnostic (18F-fluoromisonida... | [
"Adult Liver Carcinoma",
"Liver Cirrhosis"
] | [
"Stanford University"
] | [
"National Cancer Institute"
] | [
[
{
"name": "18F-Fluoromisonidazole",
"lang": "EN"
}
]
] | null |
NCT00616187 | [
{
"id_field": "org_study_id",
"id_value": [
"1931/Si.270 am 8.5.03"
]
},
{
"id_field": "secondary_id",
"id_value": [
"ATV-D-03-007G"
]
}
] | https://clinicaltrials.gov/study/NCT00616187 | Atorvastatin in Relapsing-Remitting Multiple Sclerosis | A phase II open-label baseline-to-treatment trial was designed to evaluate the safety, tolerability and efficacy of orally administered atorvastatin in patients with relapsing-remitting multiple sclerosis (RRMS). Patients with at least one gadolinium-enhancing lesion (CEL) at screening by magnetic resonance imaging (MR... | Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis | [
{
"description": "IFN-β-1a 22 µg s.c. 3 times weekly or IFN-β-1b s.c. every other day (3 months baseline) and add on oral daily 80 mg atorvastatin (9 months add on treatment)",
"name": "interferon beta treatment to add-on atorvastatin treatment",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
... | [
{
"design_group_title": "interferon",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "IFN-β-1a 22 µg s.c. 3 times weekly or IFN-β-1b s.c. every other day (3 months baseline... | [
"Relapsing Remitting Multiple Sclerosis"
] | [
"Charité - Universitätsmedizin Berlin"
] | [
"Pfizer Inc.",
"Deutsche Forschungsgemeinschaft",
"German Federal Ministry Of Education And Research"
] | [
[
{
"name": "干扰素β-1a(Biogen, Inc.)",
"lang": "CN"
},
{
"name": "Interferon Beta-1a (Biogen, Inc.)",
"lang": "EN"
},
{
"name": "インターフェロン ベータ-1a （遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "阿托伐他汀锶",
"lang": "CN"
},
{
"name": "A... | null |
NCT00227721 | [
{
"id_field": "org_study_id",
"id_value": [
"CDR0000445432"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"P30CA022453"
]
},
{
"id_field": "secondary_id",
"id_value": [
"WSU-C-2713"
]
}
] | https://clinicaltrials.gov/study/NCT00227721 | Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer | RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.<br/>PURPOSE: This phase II trial is studying ... | Phase II Trial of Weekly Gemcitabine and Docetaxel Combination Therapy for Relapsed Ovarian or Peritoneal Cancer | [
{
"description": "40 mg/m2, 30 minute IV infusion, Days 1 and 8, Every 21 days",
"name": "Docetaxel",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Taxotere®"
],
"type": "Drug"
},
{
"description": "800mg/m2, 30 minute IV infusion, Days 1 and 8, every 2... | [
{
"design_group_description": "Docetaxel, 40 mg/m2, 30 min IV infusion on Days 1 and 8, of a 21 day cycle Gemcitabine hydrochloride, 800mg/m2 30 min IV infusion on Days1 and 8, of a 21 day cycle",
"design_group_title": "Docetaxel & Gemcitabine hydrochloride",
"design_group_type": "Experimental",
"de... | [
"Ovarian Cancer",
"Peritoneal Cavity Cancer"
] | [
"Barbara Ann Karmanos Cancer Institute"
] | [
"National Cancer Institute"
] | [
[
{
"name": "盐酸吉西他滨",
"lang": "CN"
},
{
"name": "Gemcitabine Hydrochloride",
"lang": "EN"
},
{
"name": "ゲムシタビン塩酸塩",
"lang": "JP"
}
],
[
{
"name": "多西他赛",
"lang": "CN"
},
{
"name": "Docetaxel",
"lang": "EN"
},
... | null |
NCT03762395 | [
{
"id_field": "org_study_id",
"id_value": [
"19-0510; 21-3959"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"5R01HL132550-03"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
... | https://clinicaltrials.gov/study/NCT03762395 | Anti Inflammatory Lipid Mediators in Asthma Lipid Anti-Inflammtory Mediators in Asthma | The main purpose of this Phase 2 double blind, placebo controlled crossover clinical study is to demonstrate the efficacy and safety of CXA-10 in obese adult asthmatics. Obesity induces a chronic systemic inflammatory state characterized by impaired adipokine signaling, pro-inflammatory cytokine responses, inflammatory... | Anti Inflammatory Lipid Mediators in Asthma: A Double Blind Placebo Control Cross Over, Proof of Concept Study of CXA-10 to Reduce Bronchial Hyperresponsiveness in Obese Asthmatics; Lipid Anti-Inflammatory Mediators in Asthma to Reduce Hyperresponsiveness in Obese Asthmatics | [
{
"description": "6 weeks of treatment with 150 mg/day of orally administered CXA-10",
"name": "CXA-10",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"10-nitro-9(E)-octadec-9-enoic acid"
],
"type": "Drug"
},
{
"description": "6 weeks of treatment with ... | [
{
"design_group_description": "Administered orally, continuously, and daily for at least 6 weeks. Dispensed at Visit 1. Washout period of at least 4 weeks and then enter crossover phase of an additional 6 weeks. Drug will be dispensed at Visit 4.",
"design_group_title": "CXA-10",
"design_group_type": "E... | [
"Asthma",
"Obesity"
] | [
"University of Colorado Denver"
] | [
"National Heart, Lung & Blood Institute",
"National Institutes of Health"
] | [
[
{
"name": "10-硝基油酸",
"lang": "CN"
},
{
"name": "10-Nitrooleic acid",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "ALMA; LIMA"
}
] |
NCT00585507 | [
{
"id_field": "org_study_id",
"id_value": [
"04-016"
]
}
] | https://clinicaltrials.gov/study/NCT00585507 | Efficacy and Safety of 500mg of Fulvestrant | Fulvestrant has proven effective in the treatment of hormone receptor positive metastatic breast cancer. The dose used in studies so far has been well tolerated and may be too low for optimal effectiveness. In this study, a higher dose will be used to see whether an improved outcome will result. | A Phase II Multi-Center Study to Evaluate the Efficacy and Safety of 500mg of Fulvestrant (Faslodex) as a First Line Hormonal Treatment in Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer | [
{
"description": "500mg into the muscle on days 1, 15 and 29 and then every 28 days thereafter.",
"name": "Fulvestrant",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Faslodex"
],
"type": "Drug"
}
] | [
{
"design_group_description": "fulvestrant 500mg",
"design_group_title": "single",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "500mg into the muscle on days 1, 15 and 29... | [
"Breast Cancer"
] | [
"Beth Israel Deaconess Medical Center, Inc."
] | [
"The Brigham & Women's Hospital, Inc.",
"The General Hospital Corp.",
"Dana-Farber Cancer Institute, Inc.",
"University of Colorado Denver",
"Lowell General Hospital",
"University of Maryland Greenebaum Cancer Center"
] | [
[
{
"name": "氟维司群",
"lang": "CN"
},
{
"name": "Fulvestrant",
"lang": "EN"
},
{
"name": "フルベストラント",
"lang": "JP"
}
]
] | null |
NCT01821560 | [
{
"id_field": "org_study_id",
"id_value": [
"817101"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01DA030394-01A1"
]
},
{
"id_domain": "CURE (Commonwealth Universal Research Enhancement) Program",
"id_field": "second... | https://clinicaltrials.gov/study/NCT01821560 | Baclofen Effects in Cigarette Smokers | The proposed project will utilize perfusion functional magnetic resonance imaging (fMRI), a functional candidate gene association approach (of dopaminergic addictions-targeted polymorphisms), and the dopamine-modulating and gamma-aminobutyric acid (GABA) B receptor agonist, baclofen, to examine the brain and behavioral... | Baclofen Effects on Brain and Behavior in Cigarette Smokers | [
{
"name": "Baclofen",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Beklo",
"Gablofen",
"Kemstro",
"Liofen",
"Lioresal"
],
"type": "Drug"
},
{
"name": "placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type":... | [
{
"design_group_description": "Placebo-treated subjects will follow the identical schedule as Baclofen subjects.",
"design_group_title": "Sugar pill",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"intervention": [
{
... | [
"Nicotine Dependence"
] | [
"University of Pennsylvania"
] | [
"National Institute on Drug Abuse",
"National Institutes of Health"
] | [
[
{
"name": "巴氯芬",
"lang": "CN"
},
{
"name": "Baclofen",
"lang": "EN"
},
{
"name": "バクロフェン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "449583522e50555482d4329ee4aee22e",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "BAC"
}
] |
NCT02894008 | [
{
"id_field": "org_study_id",
"id_value": [
"2016-000369-22"
]
},
{
"id_field": "acronym",
"id_value": [
"Leish2a"
]
}
] | https://clinicaltrials.gov/study/NCT02894008 | A Study of a New Leishmania Vaccine Candidate ChAd63-KH | This is a study to assess the safety of a new candidate Leishmania vaccine ChAd63-KH in patients with persistent post kala azar dermal leishmaniasis (PKDL).<br/>This is a Phase II trial in patients with PKDL, to assess the safety and compare the humoral and cellular immune responses generated by the candidate vaccine i... | A Phase IIa Safety Study to Assess the Safety and Immunogenicity of a New Leishmania Vaccine Candidate ChAd63-KH | [
{
"description": "ChAd63-KH in adults and adolescents with persistent PKDL.",
"name": "ChAd63-KH",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Single intramuscular dose of ChAd63-KH, 1 x10(10)vp or, following safety review, 7.5 x 10(10)vp in adults",
"design_group_title": "ChAd63- KH",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention... | [
"Leishmaniasis, Cutaneous"
] | [
"The University of York"
] | [
"University of Khartoum"
] | [
[
{
"name": "ChAd63-KH(The University of York)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "Leish2a"
}
] |
NCT00023621 | [
{
"id_field": "org_study_id",
"id_value": [
"UCSF-U19-CA81888-BC"
]
},
{
"id_domain": "PDQ (Physician Data Query)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"CDR0000068817"
]
},
{
"id_field": "secondary_id",
"id_value": [... | https://clinicaltrials.gov/study/NCT00023621 | Celecoxib in Preventing Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome | RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. The use of celecoxib may be an effective way to prevent the development of basal cell carcinoma.<br/>PURPOSE: Randomized phase II trial to determine the effectiveness of celecoxib in preventing basal cell carcino... | A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Celecoxib in Subjects With Basal Cell Nevus Syndrome | [
{
"name": "celecoxib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"Non-melanomatous Skin Cancer"
] | [
"The University of California, San Francisco"
] | [
"National Cancer Institute"
] | [
[
{
"name": "塞来昔布",
"lang": "CN"
},
{
"name": "Celecoxib",
"lang": "EN"
},
{
"name": "セレコキシブ",
"lang": "JP"
}
]
] | null |
NCT01417000 | [
{
"id_field": "org_study_id",
"id_value": [
"ADU-CL-01"
]
},
{
"id_field": "nct_alias",
"id_value": [
"NCT01468870"
]
}
] | https://clinicaltrials.gov/study/NCT01417000 | Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer | Test the safety, immune response and efficacy of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 compared to GVAX pancreas vaccine (with cyclophosphamide) alone in adults who have failed or refused prior treatment for metastatic pancreatic cancer. | A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Administration of GVAX Pancreas Vaccine Alone or Followed by CRS-207 in Adults With Metastatic Pancreatic Adenocarcinoma | [
{
"name": "GVAX Pancreas",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"GVAX"
],
"type": "Biological"
},
{
"name": "CRS-207",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"name": "Cyclophosphamide",
... | [
{
"design_group_description": "200 mg per square meter (mg/m^2) cyclophosphamide (Cy) administered by intravenous (IV) infusion on Day 1 of Weeks 1 and 4; GVAX pancreas vaccine (GVAX, 5 × 10e8 cells) administered by intradermal injection on Day 2 of Weeks 1 and 4; CRS-207 (1 × 10e9 colony forming units [CFU]) a... | [
"Metastatic Pancreatic Cancer"
] | [
"Aduro BioTech, Inc."
] | [
"The Johns Hopkins University"
] | [
[
{
"name": "CRS-207",
"lang": "EN"
}
],
[
{
"name": "环磷酰胺",
"lang": "CN"
},
{
"name": "Cyclophosphamide",
"lang": "EN"
},
{
"name": "シクロホスファミド水和物",
"lang": "JP"
}
],
[
{
"name": "Enistimagene Setitucel/Damistimagene M... | [
{
"identifier_source": [
{
"code": "242e03a82389a88e284d228a0a225802",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "42a0488a805ee4ea8ee892e2e02a5902",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "Pha... |
NCT00872716 | [
{
"id_field": "org_study_id",
"id_value": [
"D1443L00051"
]
},
{
"id_field": "secondary_id",
"id_value": [
"EudraCT-Nr: 2008-001371-30"
]
},
{
"id_field": "acronym",
"id_value": [
"QUISS"
]
}
] | https://clinicaltrials.gov/study/NCT00872716 | Quetiapine in Specific Phobia | The study hypothesis is that quetiapine XR has anxiolytic properties. The study aims to investigate the putative anxiolytic properties of quetiapine XR in patients with anxiety disorders. Therefore, in a proof-of-concept design patients with simple phobia will be selected to investigate specific anxiolytic and antipani... | Anxiolytic Effects of Single-dose Quetiapine XR Administration on Clinical Symptoms and Amygdala Activation During Exposure in Patients With Simple Phobia | [
{
"description": "100 mg single-dose Quetiapine XR",
"name": "Quetiapine XR",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"- ATC-Code: N05A H04",
"- Seroquel Prolong",
"- Seroquel XR"
],
"type": "Drug"
},
{
"description": "Placebo",
"n... | [
{
"design_group_description": "100 mg single-dose Quetiapine XR",
"design_group_title": "Quetiapine XR",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "100 mg single-dose Q... | [
"Specific Phobia"
] | [
"Universitätsklinikum Münster"
] | [
"AstraZeneca PLC"
] | [
[
{
"name": "富马酸喹硫平",
"lang": "CN"
},
{
"name": "Quetiapine Fumarate",
"lang": "EN"
},
{
"name": "クエチアピンフマル酸塩",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "QUISS"
}
] |
NCT04130854 | [
{
"id_field": "org_study_id",
"id_value": [
"STU-2019-1492"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"5R01CA283953-03"
]
},
{
"id_field": "secondary_id",
"id_value": [
"5R01CA283953-03;STU-2019-1492"
]
... | https://clinicaltrials.gov/study/NCT04130854 | INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer | Determine the complete pathologic complete response (pCR) rate in patients with locally advanced rectal adenocarcinoma. | INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer, a Phase II Randomized Multi-center Trial With and Without APX005M, an Anti-CD40 Agonist | [
{
"description": "1. APX005M 0.3mg/kg intravenously on day 3 of radiation and on day 3 of cycles 1-5 of mFOLFOX<br/>2. Short course radiation therapy 5 Gy x 5 days<br/>3. Oxaliplatin 85mg/m2 intravenous day 1 of each cycle<br/>4. Leucovorin 400mg/m2 IV Day 1 of each cycle<br/>5. 5-FU 2400 mg/m2 continuous infus... | [
{
"design_group_description": "On Day 3 of Cycles 1-5 of each mFOLFOX treatment, participants will receive another dose of APX005M. The sequence of administration of APX005M in combination with mFOLFOX. In Cycle 6, participants will receive only mFOLFOX. After completing the last planned dose of mFOLFOX, partic... | [
"Locally Advanced Rectal Adenocarcinoma"
] | [
"The University of Texas Southwestern Medical Center"
] | [
"National Cancer Institute",
"Apexigen America, Inc."
] | [
[
{
"name": "Sotigalimab",
"lang": "EN"
}
]
] | null |
NCT02384382 | [
{
"id_field": "org_study_id",
"id_value": [
"MDV3100-18"
]
},
{
"id_domain": "Alias Study Number",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"C3431012"
]
}
] | https://clinicaltrials.gov/study/NCT02384382 | A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC) | The purpose of this study is to evaluate 18F-sodium fluoride positron-emission tomography / computed tomography (18F-NaF PET/CT) imaging as a method for determining treatment response in metastatic bone lesions in patients who are receiving enzalutamide for castration-resistant prostate cancer. | A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY OF 18F-SODIUM FLUORIDE PET/CT BONE IMAGING IN ENZALUTAMIDE-TREATED CHEMOTHERAPY-NAÏVE PATIENTS WITH BONE-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | [
{
"name": "Enzalutamide",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"MDV3100",
"Xtandi"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily",
"design_group_title": "Enzalutamide monotherapy",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"Prostate Carcinoma Metastatic to the Bone",
"Castration Resistant Prostate Cancer"
] | [
"Pfizer Inc."
] | [
"Medivation LLC (California)",
"Astellas Pharma, Inc."
] | [
[
{
"name": "恩扎卢胺",
"lang": "CN"
},
{
"name": "Enzalutamide",
"lang": "EN"
},
{
"name": "エンザルタミド",
"lang": "JP"
}
]
] | null |
NCT02660489 | [
{
"id_field": "org_study_id",
"id_value": [
"ORCA2015"
]
}
] | https://clinicaltrials.gov/study/NCT02660489 | Effect of OC459 on the Response to Rhinovirus Challenge in Asthma | The aim of this study is to assess the effectiveness of a CRTH2 receptor antagonist, OC459, in preventing or attenuating the worsening of asthma symptoms during rhinovirus infection. The study is a double blind, randomised trial in which half the subjects will receive OC459 and the other half placebo, before being inoc... | Effect of the CRTH2 Antagonist OC459 on the Response to Rhinovirus Challenge in Asthma | [
{
"name": "OC459",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"OC000459"
],
"type": "Drug"
},
{
"name": "Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Inoculation with rhinovirus sero... | [
{
"design_group_description": "OC459 50mg once daily for 5 weeks",
"design_group_title": "OC459 (CRTH2 antagonist)",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_name": "OC459",
... | [
"Asthma",
"Rhinovirus",
"Picornaviridae Infections",
"Common Cold"
] | [
"Imperial College London"
] | [
"The Medical Research Council",
"Atopix Therapeutics Ltd."
] | [
[
{
"name": "Timapiprant",
"lang": "EN"
}
]
] | null |
NCT00267709 | [
{
"id_field": "org_study_id",
"id_value": [
"291-411"
]
}
] | https://clinicaltrials.gov/study/NCT00267709 | Visilizumab for Treatment of Perianal Fistulas in Crohn's Disease | The purpose of the study is to evaluate an intravenous (by injection) investigational medication to treat Crohn's disease in patients with at least one perianal fistula. The research is being conducted at up to 5 clinical research sites in the US and Europe and is open to both men and women ages 18 to 70 years old. Par... | A Phase 2a, Open-label Study of Visilizumab for Treatment of Perianal Fistulas in Patients With Crohn's Disease | [
{
"name": "Visilizumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"Crohn's Disease"
] | [
"Abbott Biotherapeutics Corp."
] | [
"PDL BioPharma, Inc."
] | [
[
{
"name": "维西珠单抗",
"lang": "CN"
},
{
"name": "Visilizumab",
"lang": "EN"
}
]
] | null |
NCT03401112 | [
{
"id_field": "org_study_id",
"id_value": [
"IMR-SCD-102"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2017-000653-39"
]
}
] | https://clinicaltrials.gov/study/NCT03401112 | A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia) | Study of IMR-687 in adult participants with sickle cell anemia (SCA) (homozygous HbSS or sickle-β0 thalassemia). | A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study of IMR-687 in Adult Patients With Sickle Cell Anaemia (Homozygous HbSS or Sickle-β0 Thalassemia) | [
{
"description": "Oral administration of IMR-687 once daily with or without HU.",
"name": "IMR-687",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Oral administration of placebo once daily with or without HU.",
"name": "Placebo",
"normaliz... | [
{
"design_group_description": "A starting dose of IMR-687 50 mg with dose escalation after 4 or 12 weeks, up to 100 mg was administered to participants. Duration of administration was 16 (Week 17) or 24 weeks (Week 25).",
"design_group_title": "IMR-687 50 mg/100 mg",
"design_group_type": "Experimental",... | [
"Sickle Cell Disease"
] | [
"Cardurion Pharmaceuticals, Inc."
] | [
"Imara, Inc."
] | [
[
{
"name": "Tovinontrine",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "205a8282949a985239e80a5dee904a20",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "8aedd825928523eeae5535aea8d322a2",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "IMR... |
NCT07206849 | [
{
"id_field": "org_study_id",
"id_value": [
"CONNECT TarGeT-B"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. FDA Grant/Contract",
"id_value": [
"R01FD008167"
]
}
] | https://clinicaltrials.gov/study/NCT07206849 | Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG) | The goal of this study is to determine the efficacy of the study drugs tovorafenib to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (MAPK) that this drug targets.<br/>The main question the study aims to answer is whether to... | A Phase 2 Study of Tovorafenib in Pediatric and Young Adult Patients Newly Diagnosed With High-Grade Glioma (HGG), Including Diffuse Intrinsic Pontine Glioma (DIPG), Which Harbor Alterations in the Mitogen-Activated Protein Kinase (MAPK) Pathway | [
{
"description": "Tovorafenib will be given orally once weekly (QW) throughout each cycle.",
"name": "Tovorafenib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Patients with intracranial, localized, non-pontine, and non-thalamic HGG harboring a BRAFV600 mutation (who do not meet criteria for Strata B or C).",
"design_group_title": "Stratum A - localized HGG",
"design_group_type": "Experimental",
"design_group_type_normalized_... | [
"High Grade Glioma (HGG) of the Brain With BRAF Aberration",
"High Grade Glioma (III or IV)",
"Diffuse Intrinsic Pontine Glioma",
"High Grade Glioma",
"WHO Grade 3 Glioma",
"WHO Grade 4 Glioma",
"Metastatic Brain Tumor"
] | [
"Nationwide Children's Hospital"
] | [
"Day One Biopharmaceuticals, Inc."
] | [
[
{
"name": "Tovorafenib",
"lang": "EN"
}
]
] | null |
NCT02506517 | [
{
"id_field": "org_study_id",
"id_value": [
"MOBILITY-003"
]
}
] | https://clinicaltrials.gov/study/NCT02506517 | A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene | This is a phase 2 study (the second phase in testing a new drug) to see how useful an investigational drug called afatinib is in patients with advanced cancer with changes in the HER gene.<br/>Afatinib is a drug that is approved by Health Canada for the treatment of advanced lung cancer with changes in the HER gene. Af... | Molecular Basket Trial In Multiple Malignancies With Common Target Pathway Aberrancies | [
{
"name": "Afatinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"GIOTRIF"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Afatinib, orally, at a dose of 40 mg once a day, every day of each 28 day cycle.",
"design_group_title": "Afatinib",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"inter... | [
"Solid Tumors"
] | [
"University Health Network"
] | [
"Boehringer Ingelheim GmbH"
] | [
[
{
"name": "马来酸阿法替尼",
"lang": "CN"
},
{
"name": "Afatinib Dimaleate",
"lang": "EN"
},
{
"name": "アファチニブマレイン酸塩",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"code": "d23a8392245d8523a8e3a0e2a52de528",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "MOBILITY3"
}
] |
NCT01388933 | [
{
"id_field": "org_study_id",
"id_value": [
"TU100P2T2"
]
}
] | https://clinicaltrials.gov/study/NCT01388933 | A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease | The purpose of this study is to determine whether Daikenchuto(TU-100)is effective in the treatment of Crohn's disease. | A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study of Daikenchuto (TU-100) in Subjects With Moderate Crohn's Disease | [
{
"description": "15g daily, orally as 5g three times daily for 8 consecutive weeks",
"name": "TU-100",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Daikenchuto"
],
"type": "Drug"
},
{
"description": "15g as 5g three times daily, orally for 8 consecut... | [
{
"design_group_description": "15g TU-100 (oral, daily) for 8 consecutive weeks (administered as 5g three times daily)",
"design_group_title": "TU-100",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"... | [
"Crohn's Disease"
] | [
"Tsumura USA, Inc."
] | [
"Syneos Health, Inc."
] | [
[
{
"name": "Daikenchuto(Tsumura)",
"lang": "EN"
}
]
] | null |
NCT03347838 | [
{
"id_field": "org_study_id",
"id_value": [
"17-1492.cc"
]
}
] | https://clinicaltrials.gov/study/NCT03347838 | Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers | The goal of this clinical research study is to determine whether the PD-1 inhibitor (Programmed cell death protein 1) nivolumab improves premalignant bronchial dysplastic lesions in subjects that are at high risk for the development of lung cancer, including those with a prior smoking history, or history of lung cancer... | PD-1 Immune Checkpoint Inhibition for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers With or Without a History of Lung Cancer | [
{
"description": "Nivolumab is a human monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.",
"name": "Nivolumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"BMS-936558",
"MDX1106",
"ONO-4538",
"Opdivo"
... | [
{
"design_group_description": "240 mg IV every 2 weeks for 4 doses",
"design_group_title": "Nivolumab Injection [Opdivo]",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Ni... | [
"Bronchial Dysplasia",
"Tobacco Smoking",
"History of Non-Small Cell Lung Cancer",
"History of Head and Neck Cancer"
] | [
"University of Colorado Denver"
] | [
"Bristol Myers Squibb Co."
] | [
[
{
"name": "纳武利尤单抗",
"lang": "CN"
},
{
"name": "Nivolumab",
"lang": "EN"
},
{
"name": "ニボルマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT01594177 | [
{
"id_field": "org_study_id",
"id_value": [
"GBG 70"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2011-004704-38"
]
},
{
"id_field": "acronym",
"id_value": [
"DAFNE"
]
}
] | https://clinicaltrials.gov/study/NCT01594177 | Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy | Anthracycline/taxane based combination chemotherapy of at least 18 weeks represents the standard of care in the neoadjuvant setting. In HER2 positive disease trastuzumab is given simultaneously. Neoadjuvant anthracycline-taxane-based chemotherapy given simul-taneously with trastuzumab achieves a pCR rate of approx. 40%... | Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy | [
{
"description": "20 mg daily for 17 weeks (first two weeks every second day).",
"name": "Afatinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "First cycle: loading dose 8 mg/kg (day 1 q day 22), thereafter maintenance dose for 9 cycles: 6 mg/k... | [
{
"design_group_description": "Afatinib-Trastuzumab (6 weeks) followed by Afatinib*-Paclitaxel-Trastuzumab (12 weeks) followed by Epirubicin-Cyclophosphamide-Trastuzumab (12 weeks). *only 11 weeks.",
"design_group_title": "Treatment arm",
"design_group_type": "Experimental",
"design_group_type_norma... | [
"Unilateral HER2 Positive Breast Cancer"
] | [
"GBG Forschungs GmbH"
] | [
"Boehringer Ingelheim GmbH"
] | [
[
{
"name": "曲妥珠单抗",
"lang": "CN"
},
{
"name": "Trastuzumab",
"lang": "EN"
},
{
"name": "トラスツズマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "马来酸阿法替尼",
"lang": "CN"
},
{
"name": "Afatinib Dimaleate",
"lang": "EN"
},
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "DAFNE"
}
] |
NCT06798558 | [
{
"id_field": "org_study_id",
"id_value": [
"Pro2024-0079"
]
},
{
"id_domain": "Novartis",
"id_field": "secondary_id",
"id_type": "Other Grant/Funding Number",
"id_value": [
"CAAA617A1US07T"
]
},
{
"id_domain": "HMH",
"id_field": "secondary_id",
"id_ty... | https://clinicaltrials.gov/study/NCT06798558 | Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy | Male adults with a confirmed diagnosis of prostate adenocarcinoma who meet criteria for localized high risk prostate cancer according to the NCCN guidelines and who are eligible for prostatectomy will be invited to participate. Criteria for high-risk prostate cancer include patients with preoperative prostate biopsy sc... | Phase II Study of Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy | [
{
"description": "Lu-17-PSMA-617 administration",
"name": "Lu-17-PSMA-617",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Patients will receive 2 cycles of Lu-177-PSMA-617 (PluvictoⓇ) administered at the dose of 7.4 GBq (±10%), once every 6 weeks (±1 week)",
"design_group_title": "Lu-177-PSMA-617 Treatment",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561... | [
"Prostate Adenocarcinoma"
] | [
"Hackensack Meridian Health, Inc."
] | [
"Georgetown Lombardi Comprehensive Cancer Center",
"Novartis AG"
] | [
[
{
"name": "镥[177Lu] 特昔维匹肽",
"lang": "CN"
},
{
"name": "Lutetium (177 Lu) Vipivotide Tetraxetan",
"lang": "EN"
},
{
"name": "ルテチウムビピボチドテトラキセタン（１７７Ｌｕ）",
"lang": "JP"
}
]
] | null |
NCT01066364 | [
{
"id_field": "org_study_id",
"id_value": [
"091491"
]
}
] | https://clinicaltrials.gov/study/NCT01066364 | Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis | The purpose of the study is to see if the drug colesevelam is a potential treatment for Nonalcoholic Steatohepatitis(NASH). | Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis | [
{
"description": "3.75 gm/day (six 675 mg tablets)",
"name": "Colesevelam Hcl",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Welchol"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Six tablets per day (identical to colesevelam)",
"design_group_title": "Placebo (sugar) pill",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1ebb7d90a3d9b81daa54f73163ecb",
"intervention": [
{
"intervention_descript... | [
"Nonalcoholic Steatohepatitis"
] | [
"University of California San Diego"
] | [
"Daiichi Sankyo Co., Ltd."
] | [
[
{
"name": "盐酸考来维仑",
"lang": "CN"
},
{
"name": "Colesevelam Hydrochloride",
"lang": "EN"
}
]
] | null |
NCT02092142 | [
{
"id_field": "org_study_id",
"id_value": [
"S-11-19"
]
},
{
"id_domain": "MRMC",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"FY13-02"
]
}
] | https://clinicaltrials.gov/study/NCT02092142 | Safety and Immunogenicity of Q Fever Vaccine | The purpose of this study is to evaluate the safety of Q Fever Vaccine, Phase I, Inactivated, Dried, NDBR 105 and collect data on incidence of occupational Q fever infection in vaccinated personnel. | Evaluation of the Safety and Immunogenicity of Q Fever Vaccine, Phase I, Inactivated, Dried, NDBR 105, in Subjects at Risk of Exposure to Coxiella Burnetii | [
{
"description": "Subcutaneous 0.5 mL Q fever Vaccine, Phase I, Inactivated, Dried, NDBR 105",
"name": "Q fever Vaccine",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"Q fever Vaccine, Phase I, Inactivated, Dried, NDBR 105"
],
"type": "Biological"
}
] | [
{
"design_group_description": "The vaccine will be administered subcutaneously in the upper outer aspect of the arm (triceps area) with 0.5 mL Q fever Vaccine, Phase I, Inactivated, Dried, NDBR 105 (which equals 30 μg)",
"design_group_title": "Vaccinated",
"design_group_type": "Experimental",
"desig... | [
"Q Fever"
] | [
"U S Army Medical Research & Development Command"
] | [
"U.S. Army Medical Research Institute for Infectious Diseases"
] | [
[
{
"name": "Q Fever Vaccine(U.S. Army Medical Research and Development Command)",
"lang": "EN"
}
]
] | null |
NCT02794428 | [
{
"id_field": "org_study_id",
"id_value": [
"VICC GI 1527"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"6R01CA190612-03"
]
}
] | https://clinicaltrials.gov/study/NCT02794428 | Chemoprevention of Gastric Carcinogenesis | A clinical study of the efficacy of oral alpha-difluoromethylornithine (eflornithine or DFMO) in male and female subjects ages 30-60 with gastric premalignant lesions in two high risk regions of Latin America. | Targeted Chemoprevention of Gastric Carcinogenesis in High Risk Populations | [
{
"description": "Eflornithine*, 2 tablets, Oral, Daily for 18 months",
"name": "Eflornithine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Eflornithine placebo, 2 tablets, Oral, Daily for 18 months",
"name": "Eflornithine placebo",
"nor... | [
{
"design_group_title": "Eflornithine",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "Eflornithine*, 2 tablets, Oral, Daily for 18 months",
"intervention_name": "... | [
"Gastric Cancer",
"Gastric Intestinal Metaplasia"
] | [
"The Vanderbilt-Ingram Cancer Center"
] | [
"National Cancer Institute",
"Cancer Prevention Pharmaceuticals, Inc."
] | [
[
{
"name": "依氟鸟氨酸",
"lang": "CN"
},
{
"name": "Eflornithine Hydrochloride",
"lang": "EN"
}
]
] | null |
NCT04133233 | [
{
"id_field": "org_study_id",
"id_value": [
"D20180617"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2018-002777-22"
]
},
{
"id_domain": "ANSM",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
... | https://clinicaltrials.gov/study/NCT04133233 | Low Dose IL-2 Therapy in Patients With a Depressive Episode in the Course of a Bipolar Disorder | The purpose of this study will be to demonstrate improvement of the T regulatory cells (Treg) response, under add on low-dose Interleukin 2 (ld-IL2) in patients with bipolar disorders experiencing a depressive relapse | Low Dose IL-2 Therapy in Patients With a Depressive Episode in the Course of a Bipolar Disorder | [
{
"description": "Treatment administration consists in a first course of five-day treatment (induction), followed by a single injection every week for 4 weeks (maintenance; from Week 3 to Week 6)",
"name": "ILT101",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"IL2"
... | [
{
"design_group_description": "IL-2 (ILT-101) Sub-cutaneous<br/>1 million UI/j",
"design_group_title": "active treatment",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Tr... | [
"Bipolar Depression"
] | [
"Assistance Publique des Hôpitaux de Paris SA"
] | [
"ILTOO Pharma SAS"
] | [
[
{
"name": "Aldesleukin(Assistance Publique Hopitaux De Paris)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "DEPIL-2"
}
] |
NCT00693160 | [
{
"id_field": "org_study_id",
"id_value": [
"IRB00002457"
]
},
{
"id_field": "secondary_id",
"id_value": [
"GM48085"
]
}
] | https://clinicaltrials.gov/study/NCT00693160 | Effect of Spinal Ketorolac After Acute Opioid Exposure | This research study is being done because pain is a significant problem for patients with a variety of medical problems and following surgery or traumatic injury. Currently available pain medications may not treat all types of pain or may treat pain only at doses that produce side effects and complications. The medicat... | Effect of Intrathecal Ketorolac on Mechanical Hypersensitivity Following Acute Opioid Exposure | [
{
"description": "single intrathecal injection of ketorolac 2 mg",
"name": "ketorolac",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"acular pf",
"toradol"
],
"type": "Drug"
},
{
"description": "subject will receive a placebo (preservative free n... | [
{
"design_group_description": "In the presence of a remifentanil infusion subject will receive a single intrathecal injection of ketorolac 2 mg Each subject will receive the topical capsaicin model for hyperalgesia and allodynia assessment.",
"design_group_title": "Intrathecal Ketorolac",
"design_group_... | [
"Healthy"
] | [
"Wake Forest University"
] | [
"National Institute of General Medical Sciences"
] | [
[
{
"name": "辣椒碱",
"lang": "CN"
},
{
"name": "Capsaicin",
"lang": "EN"
}
],
[
{
"name": "酮咯酸氨丁三醇",
"lang": "CN"
},
{
"name": "Ketorolac Tromethamine",
"lang": "EN"
}
],
[
{
"name": "盐酸瑞芬太尼",
"lang": "CN"
},
... | null |
NCT05411146 | [
{
"id_field": "org_study_id",
"id_value": [
"ARC-19"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2022-000822-50"
]
}
] | https://clinicaltrials.gov/study/NCT05411146 | A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant, a New Compound in the Treatment of Cancer | This study will assess absorption, metabolism, and excretion of Radioactively Labeled Etrumadenant in healthy volunteers. | A Phase 1, Open-label Study to Assess the Absorption, Metabolism, and Excretion, Including the Mass Balance, of a Single Oral Dose of [14C]-Etrumadenant in Healthy Male Subjects | [
{
"description": "Administered as specified in the treatment arm.",
"name": "[14C]-etrumadenant",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"[14C]-AB928"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Participants will receive a single dose of [14C]-etrumadenant.",
"design_group_title": "[14C]-etrumadenant",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_... | [
"Healthy Participants"
] | [
"Arcus Biosciences, Inc."
] | [
"Gilead Sciences, Inc."
] | [
[
{
"name": "Etrumadenant",
"lang": "EN"
}
]
] | null |
NCT06707896 | [
{
"id_field": "org_study_id",
"id_value": [
"18224"
]
}
] | https://clinicaltrials.gov/study/NCT06707896 | TCR1020-CD8 T Cells in KRAS-mutated Cancers | This is a Phase I, open-label dose finding study to assess the safety, manufacturing feasibility, and preliminary efficacy of TCR1020-CD8 T cells in patients with KRAS-mutated cancers. Initially, patients with KRAS G12V mutation positive metastatic pancreatic adenocarcinoma or colorectal cancer will be targeted for par... | Phase I, Open-Label Study of Autologous Mutant KRAS-redirected T-cell Receptor Cells (TCR1020-CD8) | [
{
"description": "TCR1020-CD8 T cells are autologous mKRAS-redirected CD8+ T cells engineered using a lentiviral vector to express a TCR with specificity for HLA-restricted mKRAS G12V epitopes restricted to the HLA-A*11:01 molecule.",
"name": "TCR1020-CD8 T cells",
"normalized_type": "3d1aa88261d64c0384... | [
{
"design_group_description": "After lymphodepleting chemotheerapy subjects will recieve a dose of 3 x 10(8) TCR1020-CD8 T cells",
"design_group_title": "Dose Level 1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
... | [
"Metastatic Pancreatic Adenocarcinoma",
"Colorectal Cancer"
] | [
"University of Pennsylvania"
] | [
"Lustgarten Foundation",
"Stand Up To Cancer"
] | [
[
{
"name": "KRAS Mutations targeting TCR-T (University of Pennsylvania)",
"lang": "EN"
}
]
] | null |
NCT05824091 | [
{
"id_field": "org_study_id",
"id_value": [
"Gates MRI-TBD09-101"
]
}
] | https://clinicaltrials.gov/study/NCT05824091 | Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults | The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of single and then multiple doses of MK-7762 (TBD09) in healthy volunteers in the context of a first-in-human study. The effect of food on the rate and extent of absorption of a single oral dose of MK-7762 (TBD09) will also be e... | A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Trial in Healthy Adults to Evaluate the Safety, Tolerability, and PK of MK-7762 | [
{
"description": "Cohort 1: 50 mg Cohort 2: 150 mg Cohort 3: 300 mg Cohort 4: 600 mg Cohort 5: TBD Cohort 6: TBD",
"name": "MK-7762 (TBD09)",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "A subset of participants from each of the 6 dosing cohorts ... | [
{
"design_group_description": "In Part 1 of the trial (SAD/FE), up to five sequential cohorts will be enrolled to evaluate up to five escalating single doses of MK-7762; 8 participants in each cohort will be randomized (3:1) to receive MK-7762 or placebo. A sixth cohort will evaluate the effect of food on PK of... | [
"Tuberculosis"
] | [
"Bill & Melinda Gates Medical Research Institute"
] | [
"Merck Sharp & Dohme LLC"
] | [
[
{
"name": "MK-7762",
"lang": "EN"
}
]
] | null |
NCT07040072 | [
{
"id_field": "org_study_id",
"id_value": [
"TR Sta-Fin (LONG'E)"
]
},
{
"id_field": "acronym",
"id_value": [
"LONG'E"
]
}
] | https://clinicaltrials.gov/study/NCT07040072 | Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC | This is a single-arm, phase Ib study involving HNSCC patients who had received first-line treatment with either PD-1 combined with platinum-based drugs or PD-1 monotherapy. The aim of the study is to evaluate the safety and efficacy of Finotonlimab in combination with Stapokibart in the treatment of recurrent/metastati... | The Safety and Efficacy of Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, a Phase Ib Study | [
{
"description": "Receive the combination of Stapokibart and Finotonlimab in cycles 1-3, and maintain treatment with Finotonlimab in subsequent cycles.<br/>Stapokibart, 600mg for the first cycle, 300mg for the second and third cycles, administered subcutaneously every 3 weeks, for a total of 3 doses of Stapokib... | [
{
"design_group_description": "Stapokibart, 600 mg for the first cycle, 300 mg for the second and third cycles, administered subcutaneously every three weeks, for a total of 3 doses.<br/>Finotonlimab 200 mg, administered intravenously once every three weeks, until disease progression or unacceptable toxicity.",... | [
"HNSCC"
] | [
"Beijing Tongren Hospital"
] | [
"Sinocelltech Group Ltd.",
"Keymed Biosciences, Inc."
] | [
[
{
"name": "菲诺利单抗",
"lang": "CN"
},
{
"name": "Finotonlimab",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "LONG'E"
}
] |
NCT00620633 | [
{
"id_field": "org_study_id",
"id_value": [
"07-055"
]
}
] | https://clinicaltrials.gov/study/NCT00620633 | Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation | This study will test the safety of giving you specialized white cells from your donor. They are called WT1 sensitized T cells. They have been grown in the lab and are immunized against a protein. The protein is called the Wilms' tumor protein, or WT1. Your leukemic cells make too much of this protein. We want to learn ... | A Phase I Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation | [
{
"description": "Eligible patients who consent to enter this trial and for whom WT1 sensitized T cells have been generated in vitro, will receive a single dose of allogeneic WT1-sensitized T cells by bolus intravenous infusion. In this phase I trial, 6 dose levels of T cells will be evaluated, in sequential gr... | [
{
"design_group_description": "Patients with leukemia or myelodysplastic syndrome (MDS) who, following an HLA-matched allogeneic hematopoietic cell transplant, have relapsed with leukemia as demonstrated morphologically on peripheral blood smear or bone marrow aspirate",
"design_group_title": "1",
"desi... | [
"Leukemia",
"Myelodysplastic Syndrome"
] | [
"Memorial Sloan Kettering Cancer Center"
] | [
"Atara Biotherapeutics, Inc."
] | [
[
{
"name": "WT1-Sensitized Allogeneic T-Lymphocytes(Atara Biotherapeutics/Memorial Sloan Kettering Cancer Center)",
"lang": "EN"
}
]
] | null |
NCT05933668 | [
{
"id_field": "org_study_id",
"id_value": [
"YK0901"
]
}
] | https://clinicaltrials.gov/study/NCT05933668 | Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Solid Tumor | This study is a single center, open, single arm, dose increasing early clinical study. The purpose of this study is to evaluate the safety and efficacy of YK0901 immunotherapy in the treatment of patients with advanced solid tumor whose tumor antigen KRAS G12V expression is positive (HLA-A * 11:01). | Phase I Clinical Study of YK0901 Injection for the Treatment of Advanced Solid Tumors With HLA-A * 11:01 Positive and KRAS G12V Mutation | [
{
"description": "On day 0, the TCR-T cells will be administered one time. Drug: Fludarabine + Cyclophosphamide+Oxaliplatin Fludarabine: 25mg/m²/day×3days Cyclophosphamide: 300mg/m²/day×3 days Oxaliplatin：100mg×1day Drug: IL-2 After 18-24 hours of infusion of YK0901 cells, the patients will be given a small dos... | [
{
"design_group_description": "Patients will undergo lymphocytapheresis, then treatment with TCR-T cells (at escalating doses) + IL-2.Accelerated titration and \"3 + 3\" dose escalation were used in this trial . Five dose levels were set up: the dose level was 1: 1× 108 ± 20%（8×107<br/>1.2×108）; the dose level ... | [
"Advanced Solid Tumor"
] | [
"Peking University"
] | [
"Yingkai Saiwei (Beijing) Biotechnology Co., Ltd"
] | [
[
{
"name": "YK-0901",
"lang": "EN"
}
]
] | null |
NCT05379647 | [
{
"id_field": "org_study_id",
"id_value": [
"NK-002 (QN-019a)"
]
}
] | https://clinicaltrials.gov/study/NCT05379647 | Natural Killer (NK) Cell Therapy for B-Cell Malignancies | This is an open-label, Phase I study of QN-019a (allogeneic CAR-NK cells targeting CD19) as monotherapy in relapsed/refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) and in combination with Rituximab in relapsed/refractory B-cell Lymphoma.<br/>This clinical study is to evaluate the safety, tolerability and prelimi... | QN-019a as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies in Subjects With B-Cell Malignancies | [
{
"description": "Experimental Interventional Therapy",
"name": "QN-019a",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Monoclonal Antibody",
"name": "Rituximab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
... | [
{
"design_group_description": "QN-019a in Combination with Rituximab in adult subjects with r/r B-cell lymphoma.",
"design_group_title": "QN-019a in Combination with Monoclonal Antibodies",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
... | [
"B-cell Lymphoma",
"B-cell Acute Lymphoblastic Leukemia"
] | [
"Zhejiang University"
] | [
"Hangzhou Qihan Biotech Co., Ltd."
] | [
[
{
"name": "依托泊苷",
"lang": "CN"
},
{
"name": "Etoposide",
"lang": "EN"
},
{
"name": "エトポシド",
"lang": "JP"
}
],
[
{
"name": "磷酸氟达拉滨",
"lang": "CN"
},
{
"name": "Fludarabine Phosphate",
"lang": "EN"
},
{
... | null |
NCT05468164 | [
{
"id_field": "org_study_id",
"id_value": [
"17752"
]
},
{
"id_domain": "Eli Lilly and Company",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"J2G-MC-JZJQ"
]
},
{
"id_domain": "Loxo Oncology, Inc.",
"id_field": "secondary_id",
... | https://clinicaltrials.gov/study/NCT05468164 | A Study of Effect of Food and a Proton Pump Inhibitor on Selpercatinib (LY3527723) in Healthy Participants | The main purpose of this study is to assess the effect of food on how fast selpercatinib gets into the bloodstream and how long it takes the body to remove it after a high-fat meal, and the effect of a change in gastric pH after multiple doses of omeprazole on how fast selpercatinib gets into the bloodstream and how lo... | An Open-Label, Randomized, Crossover Study to Evaluate the Effect of Food and a Proton Pump Inhibitor on the Single-Dose Pharmacokinetics of LOXO-292 in Healthy Adult Subjects | [
{
"description": "Administered orally",
"name": "Selpercatinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"LOXO-292",
"LY3527723"
],
"type": "Drug"
},
{
"description": "Administered orally",
"name": "Omeprazole",
"normalized_type": "3... | [
{
"design_group_description": "Participants received:<br/>* Single oral dose of 160 mg selpercatinib administered on Day 1 of Period 1 in fasted state.<br/>* Single oral dose of 160 mg selpercatinib administered on Day 1 of Period 2 in fed state.<br/>* Multiple daily oral doses of 40 mg omeprazole administered ... | [
"Healthy"
] | [
"Eli Lilly & Co."
] | [
"Loxo Oncology, Inc."
] | [
[
{
"name": "塞普替尼",
"lang": "CN"
},
{
"name": "Selpercatinib",
"lang": "EN"
},
{
"name": "セルペルカチニブ",
"lang": "JP"
}
],
[
{
"name": "奥美拉唑",
"lang": "CN"
},
{
"name": "Omeprazole",
"lang": "EN"
},
{
"name... | null |
NCT05001373 | [
{
"id_field": "org_study_id",
"id_value": [
"IAVI G002"
]
}
] | https://clinicaltrials.gov/study/NCT05001373 | A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core) | A Phase 1, Randomized, First-in-human, Open-label Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core) in HIV-1 Uninfected Adults in Good General Health | A Phase 1, Randomized, First-in-human, Open-label Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core) in HIV-1 Uninfected Adults in Good General Health | [
{
"description": "100µg, Intramuscularly",
"name": "Core-g28v2 60mer mRNA Vaccine",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "100µg, Intramuscularly",
"name": "eOD-GT8 60mer mRNA Vaccine",
"normalized_type": "30faef638ae74cc7957c... | [
{
"design_group_description": "eOD-GT8 60mer mRNA Vaccine (100µg)",
"design_group_title": "Study Group 1",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "100µg, Intramuscul... | [
"Hiv"
] | [
"International AIDS Vaccine Initiative, Inc."
] | [
"Fred Hutchinson Cancer Research Center",
"ModernaTX, Inc.",
"University of Texas Health Science Center At San Antonio",
"George Washington University",
"Emory University"
] | [
[
{
"name": "mRNA-1645-CoreG28v2",
"lang": "EN"
}
],
[
{
"name": "mRNA-1644",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"code": "e2a382d8e2e229d0255e092952424248",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "IAVI G002"
}
] |
NCT06826313 | [
{
"id_field": "org_study_id",
"id_value": [
"VRT106-CN01"
]
}
] | https://clinicaltrials.gov/study/NCT06826313 | A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors | A Phase I Study of the Safety and Tolerability of VRT106 Administered Intravenously for Treatment of Patients With Locally Advanced or MetastaticSolid Tumors | An Open-labeled Phase I Clinical Trial Evaluating the Safety, Tolerability, Biodistribution Characteristics, Biological EEffects, and Initial Efficacy of VRT106 for Injection in the Treatment of Locally Advanced/Metastatic Solid Tumors by Intravenous Administration | [
{
"description": "Intravenous drip administration",
"name": "VRT106",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
}
] | [
{
"design_group_description": "VRT106 will be administered through IV drip",
"design_group_title": "VRT106 for injection",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "In... | [
"Solid Tumors"
] | [
"Guangzhou Virotech Pharmaceutical Co Ltd."
] | [
"The Third Affiliated Hospital, Sun Yat-Sen University"
] | [
[
{
"name": "重组溶瘤病毒M1(广州威溶特)",
"lang": "CN"
},
{
"name": "Recombinant oncolytic virus M1(Guangzhou Vitron)",
"lang": "EN"
}
]
] | null |
NCT02389751 | [
{
"id_field": "org_study_id",
"id_value": [
"2013-0815"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2015-00492"
]
},
{
"id_domain": "M D Anderson Cancer Center"... | https://clinicaltrials.gov/study/NCT02389751 | Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer | This phase I trial studies the side effects and best dose of ganetespib when given together with paclitaxel, carboplatin, and radiation therapy in treating patients with stage II-III esophageal cancer. Ganetespib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in ch... | GUARDIAN-1 Trial: A Phase 1 Study of Ganetespib in Combination With Chemoradiation for Stage II-III Esophageal Carcinoma | [
{
"description": "Given IV",
"name": "Carboplatin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Blastocarb",
"CBDCA",
"Carboplat",
"Carboplatin Hexal",
"Carboplatino",
"Carbosin",
"Carbosol",
"Carbotec",
"Displata",
... | [
{
"design_group_description": "Patients receive ganetespib IV over 1 hour, paclitaxel IV over 1 hour, and carboplatin IV over 30 minutes once a week on day 1. Patients also undergo radiation therapy 5 days a week for 5.5 weeks or for a total of 28 treatments. Treatment continues for 28 treatment days (5.5 weeks... | [
"Gastroesophageal Junction Adenocarcinoma",
"Malignant Neoplasm of the Cervical Esophagus",
"Malignant Neoplasm of the Thoracic Esophagus",
"Stage IIA Esophageal Cancer AJCC v7",
"Stage IIB Esophageal Cancer AJCC v7",
"Stage IIIA Esophageal Cancer AJCC v7",
"Stage IIIB Esophageal Cancer AJCC v7",
"Sta... | [
"The University of Texas MD Anderson Cancer Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "Ganetespib",
"lang": "EN"
}
],
[
{
"name": "卡铂",
"lang": "CN"
},
{
"name": "Carboplatin",
"lang": "EN"
},
{
"name": "カルボプラチン",
"lang": "JP"
}
],
[
{
"name": "紫杉醇",
"lang": "CN"
},
{
"na... | null |
NCT07101055 | [
{
"id_field": "org_study_id",
"id_value": [
"UQ117254-Letermovir"
]
}
] | https://clinicaltrials.gov/study/NCT07101055 | Pharmacokinetics of Oral Letermovir in Adults With End-Stage Kidney Disease With or Without Haemodialysis | This study aims to understand how the antiviral medication letermovir (PREVYMIS) is processed by the body in adults with end-stage kidney disease (ESKD), including those who are receiving intermittent haemodialysis and those who are not. Letermovir is already approved in many countries, including Australia, for prevent... | A Prospective, Open-Label, Single-Centre, Comparative Pharmacokinetic Study of Oral Letermovir (PREVYMIS) in Patients (i) Undergoing Intermittent Haemodialysis and (ii) Not Undergoing Intermittent Haemodialysis | [
{
"description": "A single 480 mg oral dose of letermovir (2 x 240 mg tablets).",
"name": "Letermovir 480 mg [PREVYMIS]",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Participants with end-stage kidney disease (ESKD) who are receiving regular intermittent haemodialysis. Each participant receives a single oral dose of letermovir (480 mg) approximately 2 hours before their scheduled dialysis session.",
"design_group_title": "ESKD undergoing i... | [
"End-Stage Kidney Disease (ESKD)"
] | [
"The University of Queensland"
] | [
"Merck Sharp & Dohme LLC",
"Royal Brisbane & WomenS Hospital"
] | [
[
{
"name": "来特莫韦",
"lang": "CN"
},
{
"name": "Letermovir",
"lang": "EN"
},
{
"name": "レテルモビル",
"lang": "JP"
}
]
] | null |
NCT06237205 | [
{
"id_field": "org_study_id",
"id_value": [
"GAUSS"
]
}
] | https://clinicaltrials.gov/study/NCT06237205 | Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency | Investigational Products: Niraparib Period: 3 years after IRB/EC approval Indication: Adult patients with histologically confirmed and locally advanced, unresectable, or metastatic solid tumors having known or suspected deleterious mutations in genes involved in homologous recombination repair (HRR) or homologous recom... | Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency (GAUSS) | [
{
"description": "a highly selective PARP1 and PARP2 inhibitor",
"name": "Niraparib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_title": "Niraparib",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "a highly selective PARP1 and PARP2 inhibitor",
"intervention_name": "Niraparib",
... | [
"Efficacy"
] | [
"Korea University Anam Hospital"
] | [
"Takeda Pharmaceutical Co., Ltd.",
"Korean Cancer Study Group"
] | [
[
{
"name": "甲苯磺酸尼拉帕利",
"lang": "CN"
},
{
"name": "Niraparib Tosylate",
"lang": "EN"
},
{
"name": "ニラパリブトシル酸塩水和物",
"lang": "JP"
}
]
] | null |
NCT03489395 | [
{
"id_field": "org_study_id",
"id_value": [
"EDO-SP-01-2015"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2015-004847-37"
]
}
] | https://clinicaltrials.gov/study/NCT03489395 | A Pilot Study on Edoxaban for the Resolution of Left Atrial Thrombosis in Patients With Non-valvular Atrial Fibrillation | Isolated reports have indicated that complete Left Atrial or Left Atrial Appendage thrombus resolution may be achieved also with use of oral Factor Xa inhibitors, which have demonstrated the same efficacy but a better safety profile compared to warfarin.<br/>The aim of this open-label pilot study is to investigate the ... | A Pilot Study on Edoxaban for the Resolution of Left Atrial Thrombosis in Patients With Non-valvular Atrial Fibrillation | [
{
"description": "Edoxaban 60 mg once a day for 4 weeks. Edoxaban 30 mg/day in patients with body weight ≤60 kg, or with concomitant therapy with verapamil/quinidine/dronedarone.",
"name": "Edoxaban",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Lixiana"
],
"... | [
{
"design_group_description": "Used for Treatment. All patients will receive edoxaban 60 mg once a day, with open-label design, for 4 weeks. Edoxaban daily dose will be reduced to 30 mg/day in case of: body weight ≤60 kg, or concomitant therapy with verapamil/quinidine/dronedarone.",
"design_group_title": "... | [
"Atrial Fibrillation"
] | [
"University of Chieti-Pescara"
] | [
"Hippocrates Research"
] | [
[
{
"name": "甲苯磺酸艾多沙班",
"lang": "CN"
},
{
"name": "Edoxaban Tosylate",
"lang": "EN"
},
{
"name": "エドキサバントシル酸塩水和物",
"lang": "JP"
}
]
] | null |
NCT05900648 | [
{
"id_field": "org_study_id",
"id_value": [
"2022-0726"
]
},
{
"id_domain": "NCI-CTRP Clinical Trials Registry",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"NCI-2023-04464"
]
}
] | https://clinicaltrials.gov/study/NCT05900648 | Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME) | To measure the level of circulating tumor DNA (ctDNA) in the blood of colorectal cancer patients after 6 months of receiving therapy with regorafenib and XmAb20717 (also known as vudalimab). ctDNA is genetic material from tumor cells that can be found and measured in the blood | Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME) | [
{
"description": "Given by PO",
"name": "Regorafenib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"BAY 73-4506"
],
"type": "Drug"
},
{
"description": "Given by (IV) vein",
"name": "XmAb20717",
"normalized_type": "3d1aa88261d64c038413723970f2b... | [
{
"design_group_description": "Participants will receive regorafenib and XmAb20717 for up to 6 cycles (6 months). Participants will take regorafenib by mouth on Days 1-21 of each cycle. Participants will rest (not take regorafenib) on Days 21-28 of each cycle. Participants will also receive XmAb20717 by vein on... | [
"Colorectal Cancer",
"Colon Cancer",
"Rectum Cancer"
] | [
"The University of Texas MD Anderson Cancer Center"
] | [
"Xencor, Inc.",
"Bayer AG"
] | [
[
{
"name": "Vudalimab",
"lang": "EN"
}
],
[
{
"name": "瑞戈非尼",
"lang": "CN"
},
{
"name": "Regorafenib",
"lang": "EN"
},
{
"name": "レゴラフェニブ水和物",
"lang": "JP"
}
]
] | null |
NCT02445131 | [
{
"id_field": "org_study_id",
"id_value": [
"CLL2-BCG"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2014-000582-47"
]
}
] | https://clinicaltrials.gov/study/NCT02445131 | Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG) | The CLL2-BCG-trial is a prospective, open-label, multicenter phase-II-trial to evaluate the efficacy and safety of a sequential regimen of a debulking with bendamustine followed by an induction with GA101 (obinutuzumab) and CAL-101 (idelalisib) followed by CAL-101 and GA101-maintenance in CLL patients | Prospective, Open-label, Multicenter Phase-II Trial to Evaluate Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by GA101 (Obinutuzumab) and CAL-101 (Idelalisib) Followed by CAL-101 and GA101 Maintenance in CLL Patients | [
{
"description": "Debulking: Cycles 1 - 2, d1 & 2: 70 mg/m2 i.v.",
"name": "Bendamustine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Induction: Cycle 1: d1: 100mg, d1(or2): 900mg, d8 & 15: 1000mg; Cycle 2-6: d1: 1000mg<br/>Maintenance: Cycle 1... | [
{
"design_group_description": "Bendamustine: 70 mg/m2 i.v. GA101: 1000 mg CAL-101: 150 mg p.o.",
"design_group_title": "Bendamustine + GA101 + CAL-101",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"... | [
"Chronic Lymphocytic Leucemia"
] | [
"German CLL Study Group"
] | [
"Hoffmann-La Roche, Inc.",
"Gilead Sciences, Inc."
] | [
[
{
"name": "盐酸苯达莫司汀",
"lang": "CN"
},
{
"name": "Bendamustine Hydrochloride",
"lang": "EN"
},
{
"name": "ベンダムスチン塩酸塩",
"lang": "JP"
}
],
[
{
"name": "艾德拉尼",
"lang": "CN"
},
{
"name": "Idelalisib",
"lang": "EN"
}
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "CLL2-BCG"
}
] |
NCT04153487 | [
{
"id_field": "org_study_id",
"id_value": [
"ASTRALI"
]
},
{
"id_field": "acronym",
"id_value": [
"ASTRALI"
]
}
] | https://clinicaltrials.gov/study/NCT04153487 | Role of Ascorbic Acid Infusion in Critically Ill Patients With Transfusion Related Acute Lung Injury | TRALI was defined as "acute noncardiogenic pulmonary edema typically occurs ≤ 6 hours following transfusion of plasma-containing blood products, such as packed red blood cells, fresh frozen plasma, platelets, or cryoprecipitate." In critically ill patients, TRALI remains the leading cause of transfusion-related fatalit... | Role of Ascorbic Acid Infusion in Critically Ill Patients With Transfusion Related Acute Lung Injury | [
{
"description": "Intermittent Intravenous Infusion of Ascorbic Acid (Vitamin C) 2.5 gm / 6 hours for 96 hours",
"name": "Ascorbic Acid Injectable Product",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Vitamin C"
],
"type": "Drug"
},
{
"description": ... | [
{
"design_group_description": "ASTRALI (AScorbic acid in TRALI) group (n=40)",
"design_group_title": "ASTRALI Group",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Intermi... | [
"Acute Lung Injury, Transfusion Related"
] | [
"Damanhour University"
] | [
"Alexandria University"
] | [
[
{
"name": "维生素C",
"lang": "CN"
},
{
"name": "Ascorbic Acid",
"lang": "EN"
},
{
"name": "アスコルビン酸",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "eed8580de2e49d95259e242daaad24a8",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "ASTRALI"
}
] |
NCT06500273 | [
{
"id_field": "org_study_id",
"id_value": [
"ALLO-501A-202"
]
},
{
"id_field": "acronym",
"id_value": [
"ALPHA3"
]
},
{
"id_field": "secondary_id",
"id_value": [
"ALLO-501A-202"
]
}
] | https://clinicaltrials.gov/study/NCT06500273 | Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL | This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use On... | A Randomized, Open-label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants With Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma | [
{
"description": "An allogeneic CAR T cell therapy targeting CD19",
"name": "cemacabtagene ansegedleucel",
"normalized_type": "288887f0545745558ff1ab1c85757552",
"other_name": [
"cema-cel"
],
"type": "Genetic"
},
{
"description": "Chemotherapy for lymphodepletion",
"name": ... | [
{
"design_group_description": "Participants receive cemacabtagene ansegedleucel following lymphodepletion regimen comprised of fludarabine and cyclophosphamide.",
"design_group_title": "cemacabtagene ansegedleucel",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562... | [
"Large B-cell Lymphoma"
] | [
"Allogene Therapeutics, Inc."
] | [
"Foresight Diagnostics, Inc."
] | [
[
{
"name": "磷酸氟达拉滨",
"lang": "CN"
},
{
"name": "Fludarabine Phosphate",
"lang": "EN"
},
{
"name": "フルダラビンリン酸エステル",
"lang": "JP"
}
],
[
{
"name": "环磷酰胺",
"lang": "CN"
},
{
"name": "Cyclophosphamide",
"lang": "EN"
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "ae2e2e380a292ed2e5532042a5222043",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "ALPHA3"
}
] |
NCT03762161 | [
{
"id_field": "org_study_id",
"id_value": [
"IIT-2018-TAS-102"
]
}
] | https://clinicaltrials.gov/study/NCT03762161 | A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer | This study evaluates the clinical benefit of TAS-102 in participants with metastatic urothelial carcinoma who are resistant to cisplatin or carboplatin front-line and checkpoint inhibitors as second line therapy. All participants will receive TAS-102 in oral form twice per day on Days 1-5 and Days 8-12 of each 28 day c... | A Phase II Study of TAS-102 in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer | [
{
"description": "Participant self-administered orally at 35 milligrams per meter squared (mg/m2) twice daily Days 1-5 and 8-12 of every 28 day cycle",
"name": "TAS 102",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_title": "Intervention TAS-102",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Participant self-administered orally at 35 milligrams per meter squared (mg/m2) t... | [
"Bladder Cancer"
] | [
"University of Kansas Medical Center"
] | [
"Taiho Oncology, Inc."
] | [
[
{
"name": "曲氟尿苷替匹嘧啶",
"lang": "CN"
},
{
"name": "Tipiracil Hydrochloride/Trifluridine",
"lang": "EN"
},
{
"name": "トリフルリジン/チピラシル塩酸塩",
"lang": "JP"
}
]
] | null |
NCT00955409 | [
{
"id_field": "org_study_id",
"id_value": [
"3134K1-2203"
]
},
{
"id_domain": "Alias Study Number",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"B2571007"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_... | https://clinicaltrials.gov/study/NCT00955409 | Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease | The purpose of this study is to assess the long term safety, tolerability, and immunogenicity of ACC-001, an investigational active immunization product+, in subjects with mild to moderate Alzheimer's disease. | A PHASE IIA, MULTICENTER, RANDOMIZED, THIRD-PARTY UNBLINDED, LONG -TERM EXTENSION STUDY TO DETERMINE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF ACC-001 WITH QS-21 ADJUVANT IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE | [
{
"description": "Vanutide Cridificar (ACC-001) 3µg + QS-21 (50µg), IM on Day 1, Month 6, Month 12 and Month 18",
"name": "ACC-001(3µg) + QS21",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "Vanutide Cridificar (ACC-001) 10µg + QS-21 (50µg),... | [
{
"design_group_description": "ACC-001(3µg) + QS21",
"design_group_title": "ACC-001(3µg) + QS21",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Vanutide Cridificar (ACC-00... | [
"Alzheimer Disease"
] | [
"Pfizer Inc."
] | [
"Janssen Alzheimer Immunotherapy Research & Development LLC"
] | [
[
{
"name": "Vanutide cridificar",
"lang": "EN"
}
]
] | null |
NCT07192237 | [
{
"id_field": "org_study_id",
"id_value": [
"2025-0933"
]
},
{
"id_domain": "NCI-CTRP Clinical Registry",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"NCI-2025-07132"
]
}
] | https://clinicaltrials.gov/study/NCT07192237 | Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia | To find out if giving blinatumomab as injections under the skin can help to control MRD and keep the disease from coming back in participants with B-cell ALL. | Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia | [
{
"description": "Given by IV",
"name": "Blinatumomab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Receiving blinatumomab as injections under the skin. The drug will be given in 35-day (5-week) treatment cycles. The injections may be given on various parts of the body, including the upper arm, thigh, stomach, and/or hips/buttocks.",
"design_group_title": "SQ blinatumomab",
... | [
"Phase 2 Study",
"Blinatumomab",
"Acute Lymphoblastic Leukemia"
] | [
"The University of Texas MD Anderson Cancer Center"
] | [
"Amgen, Inc."
] | [
[
{
"name": "贝林妥欧单抗",
"lang": "CN"
},
{
"name": "Blinatumomab",
"lang": "EN"
},
{
"name": "ブリナツモマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT04506463 | [
{
"id_field": "org_study_id",
"id_value": [
"CLR_17_17"
]
}
] | https://clinicaltrials.gov/study/NCT04506463 | Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis | This is a phase IIb, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of MM-II in subjects with symptomatic knee OA as compared to matching placebo. | A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Single-administration, Multiple-Dose Study to Demonstrate the Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis | [
{
"description": "Intra-articular injection",
"name": "MM-II dose I",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Intra-articular injection",
"name": "MM-II dose II",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Dr... | [
{
"design_group_description": "MM-II 1 ml",
"design_group_title": "Arm A",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Intra-articular injection",
"intervention_... | [
"Osteoarthritis of Knee"
] | [
"Sun Pharmaceutical Industries Ltd."
] | [
"Moebius Medical Ltd.",
"Nordic Bioscience Clinical Development VII A/S"
] | [
[
{
"name": "MM-II",
"lang": "EN"
}
]
] | null |
NCT01662921 | [
{
"id_field": "org_study_id",
"id_value": [
"APIDRL06229"
]
}
] | https://clinicaltrials.gov/study/NCT01662921 | Comparator Trial Using Insulin Glulisine vs. Insulin Lispro for Treatment of Gestational Diabetes | We hypothesize that insulin glulisine is non-inferior to currently proven rapid-acting insulin lispro when used in a basal/bolus regimen to treat hyperglycemia in patients with gestational diabetes mellitus. | Non-inferiority Trial Comparing Insulin Glulisine to Insulin Lispro as Part of a Basal-bolus Insulin Regimen for the Treatment of Gestational Diabetes. | [
{
"description": "Long acting insulin NPH dosing will be titrated weekly derived from the patients current weight and gestational age",
"name": "NPH",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Humulin N, Novolin N"
],
"type": "Drug"
},
{
"descripti... | [
{
"design_group_description": "Patients diagnosed with diabetes during pregnancy will be randomized to long acting insulin NPH and short acting insulin lispro in a basal bolus regimen to treat post prandial hyperglycemia using a dosing schedule of 50% NPH calculated by the patients weight and gestational age an... | [
"Diabetes During Pregnancy"
] | [
"Sansum Diabetes Research Institute"
] | [
"Sanofi"
] | [
[
{
"name": "谷赖胰岛素",
"lang": "CN"
},
{
"name": "Insulin Glulisine Recombinant",
"lang": "EN"
},
{
"name": "インスリン グルリジン（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "赖脯胰岛素生物类似药(Sanofi)",
"lang": "CN"
},
{
"name": "Insulin lispro... | null |
NCT01100268 | [
{
"id_field": "org_study_id",
"id_value": [
"6133"
]
}
] | https://clinicaltrials.gov/study/NCT01100268 | Enhancing Attention in Adults With Compulsive Hoarding | Available data suggest that compulsive hoarders have cognitive deficits, particularly with sustaining attention that might contribute their hoarding symptoms. | Enhancing Attention in Adults With Compulsive Hoarding: A Pilot Study | [
{
"description": "Subjects will start at 18mg/day; the dose will be increased in increments of 18mg per week to reach 72mg/day.",
"name": "Methylphenidate ER",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Concerta"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Subjects will start at 18mg/day; the dose will be increased in increments of 18mg per week to reach 72mg/day.",
"design_group_title": "Methylphenidate ER",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"... | [
"Hoarding Disorder"
] | [
"The New York State Psychiatric Institute"
] | [
"Hartford Hospital"
] | [
[
{
"name": "盐酸哌甲酯",
"lang": "CN"
},
{
"name": "Methylphenidate Hydrochloride",
"lang": "EN"
}
]
] | null |
NCT03650452 | [
{
"id_field": "org_study_id",
"id_value": [
"TAK-935-2002"
]
},
{
"id_domain": "World Health Organization",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"U1111-1206-5522"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Nu... | https://clinicaltrials.gov/study/NCT03650452 | A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies | The purpose of this study is to investigate the effect on the frequency of all seizures (convulsive and drop) in participants treated with TAK-935 compared to placebo. | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Patients With Developmental and/or Epileptic Encephalopathies | [
{
"description": "TAK-935 tablets or mini-tablets.",
"name": "TAK-935",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "TAK-935 placebo-matching tablets or mini-tablets.",
"name": "Placebo",
"normalized_type": "3d1aa88261d64c038413723970f2b5... | [
{
"design_group_description": "TAK-935 placebo-matching tablets, orally or via gastrostomy tube (G-tube)/percutaneous endoscopic gastrostomy (PEG), twice a day (BID) up to Week 20.",
"design_group_title": "Placebo",
"design_group_type": "Placebo Comparator",
"design_group_type_normalized_id": "20d1e... | [
"Epilepsy",
"Dravet Syndrome",
"Lennox-Gastaut Syndrome"
] | [
"Takeda Pharmaceutical Co., Ltd."
] | [
"Ovid Therapeutics, Inc."
] | [
[
{
"name": "Soticlestat",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "5aa9de8842e399822822958aee3ae028",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "804942aa4d92e552888282eed229a302",
"s... |
NCT02772237 | [
{
"id_field": "org_study_id",
"id_value": [
"18882"
]
}
] | https://clinicaltrials.gov/study/NCT02772237 | The Impact of Riboflavin on Sports-related Concussion | The purpose of this study is to investigate the effectiveness of riboflavin to decrease the duration of time for a student-athlete to return to participation in sports after a sports related concussion. | The Impact of Riboflavin on Sports-related Concussion: A Randomized Control Trial | [
{
"description": "Riboflavin 400mg daily",
"name": "Riboflavin",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"Vitamin B2"
],
"type": "Biological"
},
{
"name": "Placebo",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biologica... | [
{
"design_group_description": "Riboflavin 400mg daily",
"design_group_title": "Treatment group",
"design_group_type": "Active Comparator",
"design_group_type_normalized_id": "12e72981f20e3a21a1ca4a6e72a76aa7",
"intervention": [
{
"intervention_description": "Riboflavin 400mg daily"... | [
"Sports-related Concussion"
] | [
"University of Virginia"
] | [
"James Madison University"
] | [
[
{
"name": "维生素B2",
"lang": "CN"
},
{
"name": "Vitamin B2",
"lang": "EN"
}
]
] | null |
NCT04223661 | [
{
"id_field": "org_study_id",
"id_value": [
"CTO-IUSCC-0719"
]
}
] | https://clinicaltrials.gov/study/NCT04223661 | Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy | The purpose of this study is to determine if using a subject's baseline frailty score to guide the dosing of lenalidomide in a combination with dexamethasone and daratumumab (DRd lite). | Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy in Elderly, Frail Newly Diagnosed Myeloma (MMY2035) | [
{
"description": "Lenalidomide will be administered PO on Days 1 through 21 of each 28 day cycle at the dose according to the frailty score and creatinine clearance.",
"name": "Lenalidomide Pill",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "Dexa... | [
{
"design_group_description": "Starting dose of lenalidomide in subjects who are intermediately fit (frailty score of 1) will be 10 mg day 1-21 of 28 day cycle and escalate to 15 mg<br/>All subjects will receive 20mg Dexamathasone weekly (split dosing is allowed) and 16mg Daratumumab (cycle 1-2 on days 1,8,15 a... | [
"Multiple Myeloma"
] | [
"Indiana University"
] | [
"Janssen Scientific Affairs LLC"
] | [
[
{
"name": "来那度胺",
"lang": "CN"
},
{
"name": "Lenalidomide",
"lang": "EN"
},
{
"name": "レナリドミド水和物",
"lang": "JP"
}
],
[
{
"name": "达雷妥尤单抗",
"lang": "CN"
},
{
"name": "Daratumumab",
"lang": "EN"
},
{
"n... | null |
NCT03198026 | [
{
"id_field": "org_study_id",
"id_value": [
"17P.176"
]
},
{
"id_domain": "JeffTrial Number",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"JT 10049"
]
},
{
"id_field": "secondary_id",
"id_value": [
"JT 10049;17P.176"
... | https://clinicaltrials.gov/study/NCT03198026 | Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas | This phase II trial studies how well obinutuzumab and ibrutinib work as front line therapy in treating patients with indolent non-Hodgkin's lymphoma. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. Ibrutinib may stop the growth of cancer cells by blocking ... | Phase II, Single Arm, Open Label Multi-center Study of Obinutuzumab and Ibrutinib in the Front Line Treatment of Indolent Non-Hodgkin's Lymphomas | [
{
"description": "Given PO",
"name": "Ibrutinib",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-",
"2-Propen-1-one",
"936563-96-1",
"BTK Inhibitor PCI-32765",
... | [
{
"design_group_description": "Patients receive ibrutinib orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive obinutuzumab intravenously (IV) on days 1, 8, and 15 of cycle 1 and day 1 of subsequent cycles. Tr... | [
"Non-Hodgkin's Lymphoma",
"Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue",
"Ann Arbor Stage II Follicular Lymphoma",
"Ann Arbor Stage II Nodal Marginal Zone Lymphoma",
"Ann Abor Stage III B-Cell Non-Hodgkin Lymphoma",
"Ann Arbor Stage III Extranodal Marginal Zon... | [
"Sidney Kimmel Cancer Center at Thomas Jefferson University"
] | [
"Genentech, Inc.",
"Pharmacyclics LLC"
] | [
[
{
"name": "伊布替尼",
"lang": "CN"
},
{
"name": "Ibrutinib",
"lang": "EN"
},
{
"name": "イブルチニブ",
"lang": "JP"
}
],
[
{
"name": "奥妥珠单抗",
"lang": "CN"
},
{
"name": "Obinutuzumab",
"lang": "EN"
},
{
"name": ... | null |
NCT05231798 | [
{
"id_field": "org_study_id",
"id_value": [
"210933"
]
}
] | https://clinicaltrials.gov/study/NCT05231798 | Cholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and Cognition | Progressive age-related cognitive deficits occurring in both AD and DS have been connected to the degeneration of several neuronal populations, but mechanisms are not fully elucidated. The most consistent neuronal losses throughout the progression of AD are seen in cholinergic neurons where these losses negatively affe... | Cholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and Cognition | [
{
"description": "Participants will be administered an [18F]-fluoroethoxybenzovesamicol (FEOBV) radiotracer for diagnostic imaging purposes (PET scan).",
"name": "[18F]-FEOBV Radiotracer",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"[18F]-fluoroethoxybenzovesamicol"... | [
{
"design_group_description": "Adults between 18-55 with Down Syndrome.",
"design_group_title": "Down Syndrome",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Participants... | [
"Down Syndrome",
"Down Syndrome, Partial Trisomy 21",
"Alzheimer Disease"
] | [
"Vanderbilt University Medical Center"
] | [
"Vanderbilt Kennedy Center"
] | [
[
{
"name": "[18F]-FEOBV",
"lang": "EN"
}
]
] | null |
NCT05572476 | [
{
"id_field": "org_study_id",
"id_value": [
"IB 2022-01"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2022-001114-19"
]
},
{
"id_field": "acronym",
"id_value": [
"LURBIMUNE"
]
}
] | https://clinicaltrials.gov/study/NCT05572476 | Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer | Multicenter, prospective, open-labeled, 2-arm, randomized non-comparative (2:1) phase II trial assessing the efficacy of lurbinectedin in association with durvalumab | Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer | [
{
"description": "A treatment cycles consists of 3 weeks (i.e. 21 days). Lurbinectedin will be administered by intravenous infusion on Day 1 every 3 weeks.<br/>Durvalumab will be administered by intravenous infusion on Day 1 every 3 weeks.",
"name": "Association of lurbinectedin and durvalumab",
"normal... | [
{
"design_group_description": "Patients with with platinum sensitive extensive stage small-cell lung cancer (SCLC) which failed one prior platinum-containing regimen will be treated by the association of lurbinectedin and durvalumab",
"design_group_title": "Experimental Arm A: treatment by lurbinectedin and... | [
"Small Cell Lung Cancer",
"Platinum-Sensitive Lung Small Cell Carcinoma",
"Extensive-stage Small-cell Lung Cancer"
] | [
"Institut Bergonié"
] | [
"Pharma Mar SA",
"AstraZeneca PLC"
] | [
[
{
"name": "芦比替定",
"lang": "CN"
},
{
"name": "Lurbinectedin",
"lang": "EN"
}
],
[
{
"name": "度伐利尤单抗",
"lang": "CN"
},
{
"name": "Durvalumab",
"lang": "EN"
},
{
"name": "デュルバルマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "LURBIMUNE"
}
] |
NCT03026140 | [
{
"id_field": "org_study_id",
"id_value": [
"N16NCI"
]
},
{
"id_field": "secondary_id",
"id_type": "EU Trial (CTIS) Number",
"id_value": [
"2024-513314-35-00"
]
},
{
"id_field": "acronym",
"id_value": [
"NICHE"
]
},
{
"id_field": "secondary_i... | https://clinicaltrials.gov/study/NCT03026140 | Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer | In this exploratory study, patients with stage 1-3 adenocarcinoma of the colon with no signs of distant metastases will be treated with short-term immunotherapy + novel IO combinations (i.e. anti-IL 8, COX2-inhibitors, anti-LAG3). This treatment will be given during the window period until surgical resection of the tum... | Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer (Amended Protocol of: Nivolumab, Ipilimumab and COX2-inhibition in Early Stage Colon Cancer: an Unbiased Approach for Signals of Sensitivity: The NICHE TRIAL) | [
{
"description": "Nivolumab 3mg/kg (day 1 and day 15), administered neoadjuvant before surgery",
"name": "Nivolumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"nivolumab (opdivo)"
],
"type": "Drug"
},
{
"description": "Ipilimumab 1 mg/kg (day 1) ,a... | [
{
"design_group_description": "drug: ipilimumab 1 mg/kg day 1 (IV) drug: nivolumab 3 mg/kg on day 1 and day 15 (IV)",
"design_group_title": "group 1 - closed",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"Colon Carcinoma"
] | [
"Netherlands Cancer Insitute"
] | [
"Bristol Myers Squibb Co."
] | [
[
{
"name": "伊匹木单抗",
"lang": "CN"
},
{
"name": "Ipilimumab",
"lang": "EN"
},
{
"name": "イピリムマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "纳武利尤单抗",
"lang": "CN"
},
{
"name": "Nivolumab",
"lang": "EN"
},
{
... | [
{
"identifier_source": [
{
"code": "242e224e25858a5d58da43a2a8e5a35e",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "25a38a283a59e53832943e40948e5ee9",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code":... |
NCT00000229 | [
{
"id_field": "org_study_id",
"id_value": [
"NIDA-06969-11"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"R01DA006969"
]
},
{
"id_field": "secondary_id",
"id_value": [
"R01-06969-11"
]
},
{
"id_field"... | https://clinicaltrials.gov/study/NCT00000229 | Buprenorphine Detox With Two Types of Treatment. BBD II - 11 | The purpose of this study is to compare overall treatment outcome between behavioral versus enhanced behavioral treatment types. | Buprenorphine Detox With Two Types of Treatment. BBD II | [
{
"name": "Buprenorphine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
}
] | null | [
"Opioid-Related Disorders"
] | [
"University of Vermont"
] | [
"National Institute on Drug Abuse"
] | [
[
{
"name": "丁丙诺啡",
"lang": "CN"
},
{
"name": "Buprenorphine",
"lang": "EN"
},
{
"name": "ブプレノルフィン",
"lang": "JP"
}
]
] | null |
NCT00005940 | [
{
"id_field": "org_study_id",
"id_value": [
"1470.00"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2013-01361"
]
},
{
"id_field": "secondary_id",
"id_value":... | https://clinicaltrials.gov/study/NCT00005940 | Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission | This phase II trial studies how well iodine I 131 monoclonal antibody BC8, busulfan, and cyclophosphamide followed by donor stem cell transplant works in treating patients with acute myeloid leukemia that has decreased or disappeared, but the cancer may still be in the body. Giving chemotherapy drugs, such as busulfan ... | Phase II Study of Radiolabeled BC8 (Anti-CD45) Antibody Combined With Busulfan and Cyclophosphamide as Treatment for Acute Myelogenous Leukemia in First Remission Followed by HLA-Identical Related Peripheral Blood Stem Cell Transplantation | [
{
"description": "Given IV",
"name": "iodine I 131 monoclonal antibody BC8",
"normalized_type": "c030b727164e46bf9a75d711c55b9c57",
"other_name": [
"I 131 MOAB BC8",
"I 131 Monoclonal Antibody BC8",
"iodine I 131 MOAB BC8"
],
"type": "Radiation"
},
{
"description": ... | [
{
"design_group_description": "RADIOLABELED ANTIBODY: Patients receive iodine I 131 monoclonal antibody BC8 IV on day -13.<br/>CHEMOTHERAPY: Patients receive busulfan PO every 6 hours on days -7 to -4 and cyclophosphamide IV on days -3 and -2.<br/>TRANSPLANT: Patients undergo allogeneic PBSC or BM transplant on... | [
"Adult Acute Myeloid Leukemia in Remission",
"Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities",
"Adult Acute Myeloid Leukemia With Del(5q)",
"Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)",
"Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)",
"Adult Acute Myeloid Leukemia With t(16;16)(... | [
"Fred Hutchinson Cancer Research Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "环孢素",
"lang": "CN"
},
{
"name": "Cyclosporine",
"lang": "EN"
},
{
"name": "シクロスポリン",
"lang": "JP"
}
],
[
{
"name": "白消安",
"lang": "CN"
},
{
"name": "Busulfan",
"lang": "EN"
},
{
"name": "ブス... | null |
NCT06295094 | [
{
"id_field": "org_study_id",
"id_value": [
"PIPAC-OPC6"
]
},
{
"id_field": "acronym",
"id_value": [
"EPICURE"
]
}
] | https://clinicaltrials.gov/study/NCT06295094 | The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients. | The goal of this randomized clinical trial is to investigate whether pressurized intraperitoneal chemotherapy (PIPAC), delivered immediately after minimally invasive D2 gastrectomy and repeated 6-8 weeks later, improves 12-month peritoneal disease-free survival in patients with high-risk gastric adenocarcinoma when com... | The Efficacy of Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC) Combined With CURativE Intent Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients. A Multicentre, Randomised, Open-label Phase-II Study | [
{
"description": "10.5 mg/m2 body surface in 150ml saline",
"name": "Cisplatin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"description": "2.1 mg/m2 body surface in 50ml saline",
"name": "Doxorubicin",
"normalized_type": "3d1aa88261d64c038413723970f2b... | [
{
"design_group_description": "In the intervention arm, conventional pressurized intraperitoneal chemotherapy (PIPAC) with cisplatin (10.5 mg/m2 body surface in 150ml saline) and doxorubicin (2.1 mg/m2 body surface in 50ml saline) is performed through Medical Device Regulation (MDR) class IIb the CE-certified n... | [
"Gastric Cancer",
"Chemotherapy, Adjuvant",
"Peritoneal Metastases",
"Minimally Invasive Surgical Procedures"
] | [
"Odense University Hospital"
] | [
"Karolinska University Hospital"
] | [
[
{
"name": "盐酸多柔比星",
"lang": "CN"
},
{
"name": "Doxorubicin Hydrochloride",
"lang": "EN"
},
{
"name": "ドキソルビシン塩酸塩",
"lang": "JP"
}
],
[
{
"name": "顺铂",
"lang": "CN"
},
{
"name": "Cisplatin",
"lang": "EN"
},
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "EPICURE"
}
] |
NCT06987643 | [
{
"id_field": "org_study_id",
"id_value": [
"CRVO24-NFD-601"
]
},
{
"id_field": "acronym",
"id_value": [
"RESTORE"
]
},
{
"id_field": "secondary_id",
"id_value": [
"CRVO24-NFD-601"
]
}
] | https://clinicaltrials.gov/study/NCT06987643 | A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke | The purpose of this interventional study is to determine whether neflamapimod can improve residual physical disability and/or cognitive dysfunction after Moderate to Severe Acute Ischaemic Stroke. | A Double-Blind, Placebo-Controlled, Proof-of-Concept Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod on Recovery After Moderate to Severe Acute Ischaemic Stroke | [
{
"description": "Neflamapimod is a highly specific inhibitor of the intra-cellular enzyme mitogen-activated protein kinase14 (p38α) provided in 40mg capsules",
"name": "Neflamapimod",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"VX-745"
],
"type": "Drug"
}... | [
{
"design_group_description": "Neflamapimod will be administered with food for 12 weeks in subjects with Moderate to Severe Acute Ischaemic Stroke. Subjects will receive 3 capsules per day (TID) with food (i.e., with the morning, mid-day and evening meals).",
"design_group_title": "Cohort 1 neflamapimod",
... | [
"Moderate to Severe Acute Ischaemic Stroke",
"Ischaemic Stroke"
] | [
"EIP Pharma, Inc."
] | [
"CervoMed, Inc."
] | [
[
{
"name": "Neflamapimod",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "RESTORE"
}
] |
NCT07110844 | [
{
"id_field": "org_study_id",
"id_value": [
"AAAV8827"
]
},
{
"id_domain": "StandUp2Cancer (in collaboration with Janssen)",
"id_field": "secondary_id",
"id_type": "Other Grant/Funding Number",
"id_value": [
"1452862"
]
}
] | https://clinicaltrials.gov/study/NCT07110844 | Teclistamab-Daratumumab in AL Amyloidosis | The purpose of this study is to investigate whether teclistamab-daratumumab combination is effective and safe in AL amyloidosis.<br/>The study treatment is divided into cycles (C) and each cycle is 28 days (D). Study treatment is expected to last 6 months. | A Phase 2 Clinical Trial of Teclistamab and Daratumumab in Previously Untreated AL Amyloidosis | [
{
"description": "Teclistamab is a T-cell redirecting bispecific antibody (BsAb) targeting CD3 on T-cells and B-cell maturation antigen (BCMA) on plasma cells.",
"name": "Teclistamab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"TECVAYLI",
"teclistamab-cqyv"
... | [
{
"design_group_description": "All participants in this study will receive teclistamab and daratumumab.",
"design_group_title": "Teclistamab-Daratumumab",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
... | [
"Amyloid Light-chain Amyloidosis"
] | [
"Columbia University"
] | [
"Janssen Pharmaceuticals, Inc."
] | [
[
{
"name": "达雷妥尤单抗/重组人透明质酸酶PH20",
"lang": "CN"
},
{
"name": "Daratumumab/Hyaluronidase-fihj",
"lang": "EN"
},
{
"name": "ダラツムマブ（遺伝子組換え）/ボルヒアルロニダーゼ アルファ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "特立妥单抗",
"lang": "CN"
},
{
"n... | null |
NCT00434668 | [
{
"id_field": "org_study_id",
"id_value": [
"TOGA 0501"
]
},
{
"id_field": "secondary_id",
"id_value": [
"Eudra CT 2005-004029-24"
]
},
{
"id_field": "acronym",
"id_value": [
"TOLEDO"
]
}
] | https://clinicaltrials.gov/study/NCT00434668 | Evaluation of Tolerability of Adjuvant Cisplatin/Docetaxel in Completely Resected Stage IB/II Non-Small Cell Lung Cancer | The aim of this study is to evaluate the tolerability (in terms of drug delivery and toxicity) of four cycles of adjuvant docetaxel plus cisplatin in patients with completely resected stage IB-II Non-Small Cell Lung Cancer. To avoid a selection bias, eligible patients will be randomised to receive cisplatin/docetaxel o... | Randomized Phase II Study Evaluating The Tolerability Of Adjuvant Docetaxel-based Chemotherapy For Completely Resected Stage IB-II Non-Small Cell Lung Cancer (NSCLC): Toledo Trial | [
{
"name": "cisplatin/docetaxel",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "multiple_drugs",
"type": "Drug"
},
{
"name": "cisplatin/vinorelbine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "multiple_drugs",
"type": "D... | null | [
"Non-small Cell Lung Cancer"
] | [
"Antwerp University Hospital"
] | [
"Sanofi",
"University of Antwerp"
] | [
[
{
"name": "长春瑞滨双酒石酸盐",
"lang": "CN"
},
{
"name": "Vinorelbine Tartrate",
"lang": "EN"
},
{
"name": "ビノレルビン酒石酸塩",
"lang": "JP"
}
],
[
{
"name": "多西他赛",
"lang": "CN"
},
{
"name": "Docetaxel",
"lang": "EN"
},
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "TOLEDO"
}
] |
NCT01295307 | [
{
"id_field": "org_study_id",
"id_value": [
"TUD-BRIDGE-046"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2010-022584-35"
]
},
{
"id_field": "acronym",
"id_value": [
"BRIDGE"
]
}
] | https://clinicaltrials.gov/study/NCT01295307 | Clofarabine Salvage Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) | In relapsed or refractory AML allogeneic HCT is considered to be the only treatment by which long-term disease-free survival can be achieved. Despite this favorable prospect, even in younger patients with relapsed AML only about 40% of the patients reach allogeneic HCT. A number of factors contribute to this low rate o... | Clofarabine Salvage Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia | [
{
"description": "Induction and consolidation therapy / conditioning therapy with Clofarabine",
"name": "Clofarabine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "Induction therapy with clofarabine/cytarabine. Post-remission therapy with either allogeneic HCT after conditioning with clofarabine/melphalan if a donor is available, or clofarabine/cytarabine if no donor is available",
"design_group_title": "Single Arm",
"design_group_ty... | [
"Acute Myeloid Leukemia"
] | [
"Dresden University of Technology"
] | [
"Genzyme Corp."
] | [
[
{
"name": "氯法拉滨",
"lang": "CN"
},
{
"name": "Clofarabine",
"lang": "EN"
},
{
"name": "クロファラビン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "54a88aa2a8eea8aa22e98a23e32a0925",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "BRIDGE"
}
] |
NCT06440954 | [
{
"id_field": "org_study_id",
"id_value": [
"20240442"
]
},
{
"id_field": "acronym",
"id_value": [
"EPIC"
]
}
] | https://clinicaltrials.gov/study/NCT06440954 | Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases | This is a prospective interventional study clinical study to investigate the efficacy and resistance mechanisms of intrathecal pemetrexed in patients with driver gene mutations advanced NSCLC with leptomeningeal metastases. | To Investigate the Efficacy and Resistance Mechanisms of Intrathecal Pemetrexed in Advanced Non-small Cell Lung Cancer (NSCLC) Patients Harboring Oncogenic Mutations With Leptomeningeal Metastases | [
{
"description": "Intrathecal pemetrexed(50mg) twice a week for 1 week (day 1 and day 5) as induction treatment, then once monthly until progressive disease.",
"name": "Intrathecal pemetrexed",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"pemetrexed"
],
"type... | [
{
"design_group_description": "Intrathecal pemetrexed",
"design_group_title": "Intrathecal pemetrexed",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "Intrathecal pemetrexe... | [
"Non-Small Cell Lung Cancer"
] | [
"Hunan Cancer Hospital"
] | [
"Hunan Cancer Hospital"
] | [
[
{
"name": "培美曲塞二钠",
"lang": "CN"
},
{
"name": "Pemetrexed Disodium Hydrate",
"lang": "EN"
},
{
"name": "ペメトレキセドナトリウム水和物",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "EPIC"
}
] |
NCT03911076 | [
{
"id_field": "org_study_id",
"id_value": [
"PVX2TACIN17368"
]
},
{
"id_field": "acronym",
"id_value": [
"PVX2"
]
}
] | https://clinicaltrials.gov/study/NCT03911076 | Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL | * To evaluate the safety and tolerability of the dual IM pNGVL4a Sig/E7(detox)/HSP70 DNA and single IM TA-CIN immunization regimen<br/>* To evaluate the efficacy of dual IM pNGVL4a-Sig/E7(detox)/HSP70 DNA and single IM TA-CIN immunization regimen on Human Papillomavirus (HPV) 16 clearance by Month 6 | A Randomized Double-Blind, Placebo-controlled Phase II Trial With Safety Run-In of Intramuscular pNGVL4a-Sig/E7(Detox)/HSP70 and TA-CIN for the Treatment of Patients With HPV16+ Atypical Squamous Cells of Undetermined Significance (ASC-US) or Cannot Exclude High Grade SIL (ASC-H) Cytology or Low-grade Squamous Intraepi... | [
{
"description": "pNGVL4a-Sig/E7(detox)/HSP70 (pBI-1, naked DNA plasmid priming vaccine) TA-CIN (HPV16 L2E7E6 fusion protein booster vaccine)",
"name": "PVX-2",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"description": "PBS and PGC",
"name": "Placebo... | [
{
"design_group_description": "Prime: 3 mg pNGVL4a-Sig/E7(detox)/HSP70 DNA Boost: 0.1 mg TA-CIN protein",
"design_group_title": "PVX-2",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_des... | [
"ASC-US",
"ASC-H",
"LSIL"
] | [
"Papivax Biotech, Inc."
] | [
"PAREXEL International Corp."
] | [
[
{
"name": "pNGVL4a-Sig/E7(Detox)/HSP70 and TA-CIN(Papivax Biotech, Inc.)",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "aae4e20523a08482a8a02e032eeae22a",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "PVX2"
}
] |
NCT01940250 | [
{
"id_field": "org_study_id",
"id_value": [
"02EI"
]
}
] | https://clinicaltrials.gov/study/NCT01940250 | Magnesium Sulphate for Severe Hand, Foot and Mouth Disease in Vietnam | Hand foot and mouth disease (HFMD) is a common infectious disease caused by a number of different viruses - a small proportion of children infected with a particular type of enterovirus (EV71) develop neurological and systemic complications that may prove fatal. Very large epidemics of EV71 related HFMD have occurred a... | A Randomized, Placebo-controlled, Double-blind Trial of Intravenous Magnesium Sulfate for the Management of Severe Hand, Foot and Mouth Disease With Autonomic Nervous System Dysregulation in Vietnamese Children. | [
{
"description": "MgSO4 IV infusion",
"name": "Magnesium Sulphate",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"magnesi sulfat krabi 15%"
],
"type": "Drug"
},
{
"description": "H2O IV infusion",
"name": "Sterile water",
"normalized_type": "3d... | [
{
"design_group_description": "Sterile water will be packaged identically to the active comparator.<br/>Each patient randomized to the placebo arm of the trial will receive a loading dose of 0.5ml/kg intravenous over 20 minutes , followed by a maintenance dose of 0.3 ml/kg/hr to 0.5 ml/kg/hr randomly adjusted b... | [
"Hand, Foot and Mouth Disease"
] | [
"Clinical Trial Service Unit"
] | [
"Childrens Hospital 1"
] | [
[
{
"name": "硫酸镁",
"lang": "CN"
},
{
"name": "Magnesium Sulfate",
"lang": "EN"
},
{
"name": "硫酸マグネシウム水和物",
"lang": "JP"
}
]
] | null |
NCT00217568 | [
{
"id_field": "org_study_id",
"id_value": [
"PSOC 1702"
]
},
{
"id_field": "secondary_id",
"id_value": [
"PSOC-1702"
]
},
{
"id_field": "secondary_id",
"id_value": [
"AVENTIS-PSOC-1702"
]
},
{
"id_field": "secondary_id",
"id_value": [
"... | https://clinicaltrials.gov/study/NCT00217568 | Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity Cancer | RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.<br/>PURPOSE: This phase II trial is studying ... | A Phase II Trial of Docetaxel and Carboplatin for First Relapsed Platinum-Sensitive Stage III and IV Advanced Ovarian Cancer or Peritoneal Carcinoma | [
{
"name": "pegfilgrastim",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"type": "Biological"
},
{
"name": "carboplatin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name": "docetaxel",
"normalized... | null | [
"Ovarian Cancer",
"Peritoneal Cavity Cancer"
] | [
"Fred Hutchinson Cancer Research Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "卡铂",
"lang": "CN"
},
{
"name": "Carboplatin",
"lang": "EN"
},
{
"name": "カルボプラチン",
"lang": "JP"
}
],
[
{
"name": "多西他赛",
"lang": "CN"
},
{
"name": "Docetaxel",
"lang": "EN"
},
{
"name": "ドセ... | null |
NCT06523621 | [
{
"id_field": "org_study_id",
"id_value": [
"IRB00118367"
]
},
{
"id_domain": "AHWFBCCC",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"LCI-PCD-RRMM-NIVO-001"
]
},
{
"id_domain": "Advarra IRB",
"id_field": "secondary_id",
"i... | https://clinicaltrials.gov/study/NCT06523621 | Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel | This study is designed to evaluate if treatment with adjuvant nivolumab improves depth of response in patients with relapsed refractory multiple myeloma (RRMM) who achieve a less-than-ideal response to idecaptagene vicleucel. | Nivolumab As An Adjunctive Therapy In Relapsed Refractory Multiple Myeloma Patients With Sub-Optimal Response To Idecabtagene Vicleucel | [
{
"description": "2 cycles of nivolumab at a dose of 480 mg given over approximately 30-minutes intravenously on Day 1 of each treatment cycle",
"name": "Nivolumab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Opdivo"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Nivolumab",
"design_group_title": "Single Arm",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "2 cycles of nivolumab at a dose of 480 mg give... | [
"Multiple Myeloma"
] | [
"Wake Forest School of Medicine"
] | [
"Bristol Myers Squibb Co."
] | [
[
{
"name": "纳武利尤单抗",
"lang": "CN"
},
{
"name": "Nivolumab",
"lang": "EN"
},
{
"name": "ニボルマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT01158651 | [
{
"id_field": "org_study_id",
"id_value": [
"DOD W81XWH-05-1-0615"
]
},
{
"id_domain": "UAB F100225004",
"id_field": "secondary_id",
"id_type": "Other Grant/Funding Number",
"id_value": [
"UAB"
]
},
{
"id_field": "nct_alias",
"id_value": [
"NCT006529... | https://clinicaltrials.gov/study/NCT01158651 | Everolimus for Children With NF1 Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas | The purpose of this research study is to learn if the study drug RAD001 can shrink or slow the growth of low-grade gliomas in children with Neurofibromatosis type 1 (NF1). Additionally, the safety of RAD001 will be studied.<br/>The study drug, RAD001, is a drug that may act directly on tumor cells by preventing tumor c... | A Phase II Study of RAD001 (Everolimus) for Children With NeurF1 and Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas | [
{
"description": "If you take part in this research study, you will be given a participant diary for each treatment course to help you keep track of when you take your RAD001. You will be required to bring the completed diary at each scheduled visit. A treatment \"course\" lasts 4 weeks and there will not be an... | [
{
"design_group_description": "If you take part in this research study, you will be given a participant diary for each treatment course to help you keep track of when you take your RAD001. You will be required to bring the completed diary at each scheduled visit. A treatment \"course\" lasts 4 weeks and there w... | [
"Glioma"
] | [
"The University of Alabama at Birmingham"
] | [
"The University of Chicago",
"National Cancer Institute",
"University of Utah",
"Washington University School of Medicine",
"The Children's Hospital Corp.",
"Ann & Robert H. Lurie Children's Hospital of Chicago",
"The Children's Hospital of Philadelphia",
"Children's Hospital Los Angeles",
"NYU Lang... | [
[
{
"name": "依维莫司",
"lang": "CN"
},
{
"name": "Everolimus",
"lang": "EN"
},
{
"name": "エベロリムス",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "e48aad522ae354d23d944a8225e45892",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "NFC-RAD001"
}
] |
NCT01005576 | [
{
"id_field": "org_study_id",
"id_value": [
"TCRN-NMD 0901"
]
},
{
"id_field": "acronym",
"id_value": [
"URTH"
]
}
] | https://clinicaltrials.gov/study/NCT01005576 | Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia | This study is being done to determine if blood cell transplants, with either bone marrow or cord blood from unrelated donors, are effective in children with severe thalassemia and if this treatment approach has acceptable risks and side effects.<br/>This study includes a preparative regimen with Hydroxyurea, Alemtuzuma... | A Pilot Trial of Unrelated Donor Hematopoietic Cell Transplantation for Children With Severe Thalassemia Using a Reduced Intensity Conditioning Regimen (The URTH Trial) | [
{
"description": "Days -50 to -21: Hydroxyurea 30mg/kg po Day -22: Alemtuzumab 3mg IV Day -21: Alemtuzumab 10mg IV Day -20: Alemtuzumab 15mg IV Day -19: Alemtuzumab 20mg IV Day -8: Fludarabine 30mg/m2 IV Day -7: Fludarabine 30mg/m2 IV Day -6: Fludarabine 30mg/m2 IV Day -5: Fludarabine 30mg/m2 IV Day -4: Fludara... | [
{
"design_group_description": "Hydroxyurea days -50 to -21 Alemtuzumab days -21 to -19 Fludarabine days -8 to -4 Thiotepa day -4 Melphalan day -3 Stem cell infusion day 0",
"design_group_title": "Conditioning regimen",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561... | [
"Severe Thalassemia"
] | [
"Washington University School of Medicine"
] | [
"Pediatric Blood & Marrow Transplant Co.",
"Carelon Research, Inc."
] | [
[
{
"name": "磷酸氟达拉滨",
"lang": "CN"
},
{
"name": "Fludarabine Phosphate",
"lang": "EN"
},
{
"name": "フルダラビンリン酸エステル",
"lang": "JP"
}
],
[
{
"name": "美法仑",
"lang": "CN"
},
{
"name": "Melphalan",
"lang": "EN"
},
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "5adee0ee5498a20a8500ea524228a022",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
}
],
"value": "URTH"
}
] |
NCT00006105 | [
{
"id_field": "org_study_id",
"id_value": [
"9193"
]
},
{
"id_field": "secondary_id",
"id_value": [
"UCCRC-9193"
]
},
{
"id_field": "secondary_id",
"id_value": [
"UCCRC-CTRC-9806"
]
},
{
"id_field": "secondary_id",
"id_value": [
"NCI-G0... | https://clinicaltrials.gov/study/NCT00006105 | Gemcitabine, Cisplatin, and Amifostine Following Surgery in Treating Patients With Locally Advanced Bladder Cancer | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.<br/>PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine, cisplatin, a... | Phase II Trial of Adjuvant Gemcitabine Plus Cisplatin With Amifostine Cytoprotection in Patients With Locally Advanced Bladder Cancer | [
{
"name": "amifostine trihydrate",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "cisplatin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
},
{
"name": "gemcitabine hydrochloride",
"normalized_type": "3d1aa88261d64... | [
{
"design_group_description": "Subjects receive the study drug combination in 29-day cycles. Gemcitabine (1000 mg/m2) is given by IV infusion on Days 1, 8, and 15 of each cycle. Cisplatin (70 mg/m2) is given by IV infusion on Day 1 of each cycle. Immediately prior to each cisplatin infusion amifostine (910 mg/m... | [
"Bladder Cancer",
"Drug/Agent Toxicity by Tissue/Organ"
] | [
"The University of Chicago"
] | [
"National Cancer Institute"
] | [
[
{
"name": "盐酸吉西他滨",
"lang": "CN"
},
{
"name": "Gemcitabine Hydrochloride",
"lang": "EN"
},
{
"name": "ゲムシタビン塩酸塩",
"lang": "JP"
}
],
[
{
"name": "顺铂",
"lang": "CN"
},
{
"name": "Cisplatin",
"lang": "EN"
},
{... | null |
NCT01991028 | [
{
"id_field": "org_study_id",
"id_value": [
"BC-180-12"
]
}
] | https://clinicaltrials.gov/study/NCT01991028 | A Study to Investigate Lung Deposition of Radiolabelled OligoG | OligoG is a new potential treatment which is being developed by AlgiPharma AS (a Norwegian-based company) with an aim to help people with cystic fibrosis in the future.<br/>OligoG, derived from marine algae, is expected to act locally in the lungs once inhaled to reduce mucus thickness and improve mucus clearance. It c... | An Open Label, Randomised, Two-way Crossover Scintigraphic Study to Investigate Lung Deposition of Radiolabelled OligoG Delivered as a Dry Powder and as a Nebulised Solution in Cystic Fibrosis Patients | [
{
"description": "Inhalation with dry powder by Mia Monodose Inhaler",
"name": "Radiolabelled OligoG CF-5/20 DPI",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Radiolabelled OligoG CF-5/20 Dry Powder for Inhalation"
],
"type": "Drug"
},
{
"description... | [
{
"design_group_description": "Single dose OligoG CF-5/20 Dry Powder for Inhalation by 3 capsules of 32mg OligoG via Miat Monodose Inhaler, radiolabelled ca10MBq 99mTc.",
"design_group_title": "Radiolabelled OligoG CF-5/20 DPI",
"design_group_type": "Experimental",
"design_group_type_normalized_id":... | [
"Cystic Fibrosis"
] | [
"Bdd Pharma Ltd"
] | [
"AlgiPharma AS"
] | [
[
{
"name": "Oligo-G",
"lang": "EN"
}
]
] | null |
NCT00063401 | [
{
"id_field": "org_study_id",
"id_value": [
"CA225-009"
]
},
{
"id_field": "nct_alias",
"id_value": [
"NCT00070044"
]
}
] | https://clinicaltrials.gov/study/NCT00063401 | Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer | The purpose of this study is to determine the progression-free survival obtained with cetuximab (C225)/paclitaxel/carboplatin in subjects with newly diagnosed advanced stage ovarian, primary peritoneal, or fallopian tube cancer. | A Phase II Study of Cetuximab (C225)/Paclitaxel/Carboplatin for the Initial Treatment of Advanced Stage Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | [
{
"description": "400 mg/m2 loading dose, 250 mg/m2 weekly, six 21-day cycles",
"name": "Cetuximab:",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"Erbitux"
],
"type": "Biological"
},
{
"description": "175 mg/m2 Day 1, six 21-day cycles",
"name": "... | [
{
"design_group_description": "Cetuximab 400 mg/m2 IV (over 120 minutes) on Day 1 of Cycle 1, followed by weekly maintenance doses of 250 mg/m2 IV (over 60 minutes). Paclitaxel 175 mg/m2 IC (over 3 hours) and carboplatin AUC of 6 IV (over 30 minutes) on Day 1 of each cycle. For eligible subjects, maintenance th... | [
"Ovarian Cancer",
"Peritoneal Neoplasms",
"Fallopian Tube Neoplasms"
] | [
"Eli Lilly & Co."
] | [
"Bristol Myers Squibb Co."
] | [
[
{
"name": "西妥昔单抗",
"lang": "CN"
},
{
"name": "Cetuximab",
"lang": "EN"
},
{
"name": "セツキシマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "白蛋白结合型紫杉醇",
"lang": "CN"
},
{
"name": "Albumin-Bound Paclitaxel",
"lang": "EN"
... | null |
NCT01302483 | [
{
"id_field": "org_study_id",
"id_value": [
"SR 2-01"
]
}
] | https://clinicaltrials.gov/study/NCT01302483 | Safety and Effectiveness of Kovacaine Nasal Spray for Dental Anesthesia | The purpose of this study was to determine the safety and efficacy of Kovacaine Mist (3% tetracaine HCl with 0.05% oxymetazoline HCl) for anesthesia of the maxillary teeth for dental procedures. | A Phase II, Single-Center, Randomized, Double-Blind, Active-Treatment-Controlled, Parallel-Group Study of the Efficacy of Kovacaine Nasal Spray for Anesthetizing Maxillary Teeth in Healthy Dental Patients | [
{
"description": "1 sham injection along with 3 sprays of Kovacaine Nasal Spray in each nostril; a 4-minute interval between every set of sprays. The total dose of 3% tetracaine HCL with 0.05% oxymetazoline HCL was 18 mg/0.3 mg.",
"name": "3% tetracaine HCL with 0.05% oxymetazoline HCL",
"normalized_typ... | [
{
"design_group_description": "3% tetracaine HCL with 0.05% oxymetazoline HCL - Delivered via 3 sprays (100 uL) in each nostril",
"design_group_title": "Kovacaine Nasal Spray",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"interventi... | [
"Dental Anesthesia Efficacy"
] | [
"St. Renatus LLC"
] | [
"Ground Zero Pharmaceuticals",
"Rho, Inc."
] | [
[
{
"name": "盐酸羟甲唑啉",
"lang": "CN"
},
{
"name": "Oxymetazoline Hydrochloride",
"lang": "EN"
},
{
"name": "オキシメタゾリン塩酸塩",
"lang": "JP"
}
],
[
{
"name": "盐酸丁卡因",
"lang": "CN"
},
{
"name": "Tetracaine Hydrochloride",
"la... | null |
NCT01165372 | [
{
"id_field": "org_study_id",
"id_value": [
"02MA"
]
}
] | https://clinicaltrials.gov/study/NCT01165372 | Study of Malaria Treatment at Phuoc Long Hospital, Binh Phuoc Province, Vietnam | Background: There are worrying signs from Western Cambodia that parasitological responses to artesunate containing treatment regimens for uncomplicated falciparum malaria are slower than elsewhere in the world. Delayed parasite clearance and unusually high failure rates with artesunate-mefloquine have been reported. Th... | Clinical Investigation of In-vivo Susceptibility of P. Falciparum to Artesunate in Phuoc Long Hospital, Binh Phuoc Province, Vietnam | [
{
"description": "artesunate 2mg/kg/day, artesunate 4mg/kg/day or dihydroartemisinin-piperaquine once daily",
"name": "Artesunate or dihydroartemisinin-piperaquine",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_description": "People with uncomplicated malaria who meet the study inclusion criteria will be enrolled, screened, randomized and treated on site with artesunate 2mg/kg/day for 3 days and followed by DHA-PPQ treatment at doses according to National guidelines for 3 days.",
"design_group_titl... | [
"Malaria"
] | [
"Clinical Trial Service Unit"
] | [
"World Health Organization (United States)"
] | [
[
{
"name": "青蒿琥酯",
"lang": "CN"
},
{
"name": "Artesunate",
"lang": "EN"
}
],
[
{
"name": "双氢青蒿素哌喹",
"lang": "CN"
},
{
"name": "Piperaquine tetraphosphate/Artenimol",
"lang": "EN"
}
]
] | null |
NCT05824728 | [
{
"id_field": "org_study_id",
"id_value": [
"IRB00318189"
]
},
{
"id_field": "acronym",
"id_value": [
"AGB101 PDP"
]
}
] | https://clinicaltrials.gov/study/NCT05824728 | Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis | This clinical trial will test whether AGB101 (low-dose levetiracetam, 220 mg, extended release tablet) can improve symptoms of psychosis in Parkinson's disease. Participants will be asked to complete up to 5 in-person study visits over approximately 20 weeks. Participants will receive both AGB101 and a placebo to take ... | Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis | [
{
"description": "low-dose levetiracetam, 220 mg, extended release tablet",
"name": "AGB101",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"levetiracetam"
],
"type": "Drug"
}
] | [
{
"design_group_description": "AGB101 (low-dose levetiracetam, 220 mg, extended release tablet) once daily for 6 weeks, washout (4 weeks), then placebo capsule once daily for 6 weeks.",
"design_group_title": "AGB101 first, then placebo",
"design_group_type": "Experimental",
"design_group_type_normal... | [
"Parkinson Disease Psychosis"
] | [
"The Johns Hopkins University"
] | [
"AgeneBio, Inc."
] | [
[
{
"name": "左乙拉西坦",
"lang": "CN"
},
{
"name": "Levetiracetam",
"lang": "EN"
},
{
"name": "レベチラセタム",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "AGB101 PDP"
}
] |
NCT04484935 | [
{
"id_field": "org_study_id",
"id_value": [
"D5290C00008"
]
},
{
"id_field": "secondary_id",
"id_type": "EudraCT Number",
"id_value": [
"2021-003221-30"
]
},
{
"id_field": "acronym",
"id_value": [
"MUSIC"
]
}
] | https://clinicaltrials.gov/study/NCT04484935 | Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children | Study D5290C00008 is a Phase 2, open-label, uncontrolled, single-dose study to evaluate the safety and tolerability, pharmacokinetic(s) (PK), occurrence of antidrug antibody (ADA), and efficacy of nirsevimab in immunocompromised children who are ≤ 24 months of age at the time of dose administration. Approximately 100 s... | A Phase 2, Open-label, Uncontrolled, Single-dose Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Occurrence of Antidrug Antibody for Nirsevimab in Immunocompromised Children ≤ 24 Months of Age | [
{
"description": "Single fixed IM dose of nirsevimab 50 mg if body weight < 5 kg or 100 mg if body weight ≥ 5 kg, and subjects entering their second RSV season will receive a single fixed IM dose of nirsevimab 200 mg",
"name": "Nirsevimab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"oth... | [
{
"design_group_description": "1st RSV season: 50mg nirsevimab<br/>1. st RSV season: 100mg nirsevimab<br/>2. nd RSV season: 200mg nirsevimab",
"design_group_title": "Nirsevimab",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"interven... | [
"RSV Infection"
] | [
"AstraZeneca PLC"
] | [
"IQVIA Holdings, Inc."
] | [
[
{
"name": "尼塞韦单抗",
"lang": "CN"
},
{
"name": "Nirsevimab",
"lang": "EN"
},
{
"name": "ニルセビマブ（遺伝子組換え） （JAN）",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"code": "0845892ea05eae22e5a2e29585a52d82",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "MUSIC"
}
] |
NCT00294931 | [
{
"id_field": "org_study_id",
"id_value": [
"SCRI LUN 90"
]
},
{
"id_field": "secondary_id",
"id_value": [
"AVF3256s"
]
}
] | https://clinicaltrials.gov/study/NCT00294931 | Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer | This multicenter phase II trial is designed to study the unique combination of chemotherapy (irinotecan./carboplatin) and bevacizumab in the extensive-stage setting. This clinical setting seems ideal for evaluation of the role of bevacizumab in delaying progression and prolonging survival. | A Phase II Trial of Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer | [
{
"name": "irinotecan",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name": "carboplatin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"single_or_multi": "single_drug",
"type": "Drug"
},
{
"name":... | null | [
"Carcinoma, Small Cell Lung"
] | [
"Scri Development Innovations LLC"
] | [
"Genentech, Inc."
] | [
[
{
"name": "卡铂",
"lang": "CN"
},
{
"name": "Carboplatin",
"lang": "EN"
},
{
"name": "カルボプラチン",
"lang": "JP"
}
],
[
{
"name": "贝伐珠单抗",
"lang": "CN"
},
{
"name": "Bevacizumab",
"lang": "EN"
},
{
"name": ... | null |
NCT03087071 | [
{
"id_field": "org_study_id",
"id_value": [
"2016-0338"
]
},
{
"id_domain": "CTRP (Clinical Trial Reporting Program)",
"id_field": "secondary_id",
"id_type": "Registry Identifier",
"id_value": [
"NCI-2017-00868"
]
},
{
"id_domain": "M D Anderson Cancer Center"... | https://clinicaltrials.gov/study/NCT03087071 | Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer | This phase II clinical trial studies how well panitumumab with or without trametinib works in treating patients with stage IV colorectal cancer. Immunotherapy with monoclonal antibodies, such as panitumumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow a... | A Phase II Enrichment Study of Panitumumab as a Single Agent or in Combination With Trametinib in Anti-EGFR-Refractory Stage IV Colorectal Cancer Patients | [
{
"description": "Correlative studies",
"name": "Laboratory Biomarker Analysis",
"normalized_type": "ffd65a2d86954c7285f258adfa9c2916",
"type": "Other"
},
{
"description": "Given IV",
"name": "Panitumumab",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
... | [
{
"design_group_description": "Patients with EGFR ectodomain mutation receive panitumumab IV over 30-90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Cohort 2.",
"design_group_title": "Cohort 1... | [
"EGFR NP_005219.2:p.S492R",
"KRAS Gene Mutation",
"MAP2K1 Gene Mutation",
"Metastatic Colorectal Adenocarcinoma",
"Refractory Colorectal Adenocarcinoma",
"Stage IV Colorectal Cancer AJCC v7",
"Stage IVA Colorectal Cancer AJCC v7",
"Stage IVB Colorectal Cancer AJCC v7"
] | [
"The University of Texas MD Anderson Cancer Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "二甲基亚砜曲美替尼",
"lang": "CN"
},
{
"name": "Trametinib dimethyl sulfoxide",
"lang": "EN"
},
{
"name": "トラメチニブ ジメチルスルホキシド付加物",
"lang": "JP"
}
],
[
{
"name": "帕尼单抗",
"lang": "CN"
},
{
"name": "Panitumumab",
"la... | null |
NCT00130689 | [
{
"id_field": "org_study_id",
"id_value": [
"05-113"
]
}
] | https://clinicaltrials.gov/study/NCT00130689 | Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer | Purpose: There remains a great need for novel therapeutic agents and treatment strategies for advanced esophagogastric cancer. Preclinical and clinical studies have demonstrated increased EGFR expression in a significant proportion of both esophageal and gastric carcinomas. Inactivation of EGFR through use of a monoclo... | A Phase II Trial of Cetuximab in Unresectable or Metastatic Esophageal and Gastric Carcinoma | [
{
"name": "Cetuximab",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"erbitux"
],
"type": "Drug"
}
] | [
{
"design_group_description": "Patients received cetuximab at an initial dose of 400 mg/m2 administered IV over 120 min, followed by weekly infusions at 250 mg/m2 administered IV over 60 min. Once cycle was 4 weeks of therapy. Patients received treatment until disease progression or unacceptable toxicity.",
... | [
"Esophageal Cancer",
"Gastric Cancer",
"Neoplasm Metastasis"
] | [
"Dana-Farber Cancer Institute, Inc."
] | [
"The General Hospital Corp.",
"Bristol Myers Squibb Co.",
"Beth Israel Deaconess Medical Center, Inc."
] | [
[
{
"name": "西妥昔单抗",
"lang": "CN"
},
{
"name": "Cetuximab",
"lang": "EN"
},
{
"name": "セツキシマブ（遺伝子組換え）",
"lang": "JP"
}
]
] | null |
NCT04523922 | [
{
"id_field": "org_study_id",
"id_value": [
"Pro00103198"
]
},
{
"id_field": "acronym",
"id_value": [
"COPE+OT"
]
}
] | https://clinicaltrials.gov/study/NCT04523922 | Oxytocin to Enhance Integrated Treatment for AUD and PTSD | The primary objective of the proposed Stage II study is to examine the efficacy of oxytocin (OT) as compared to placebo in reducing (1) alcohol use disorder (AUD) symptoms, and (2) post-traumatic stress disorder (PTSD) symptoms among Veterans receiving COPE therapy (Concurrent Treatment of PTSD and Substance Use Disord... | Oxytocin to Enhance Integrated Exposure-Based Treatment of Co-occurring Alcohol Use Disorder and PTSD | [
{
"description": "40 IU Intranasal Oxytocin self administered 30 minutes prior to each COPE session.",
"name": "40 IU Intranasal Oxytocin",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"oxytocin"
],
"type": "Drug"
},
{
"description": "Placebo (intranas... | [
{
"design_group_description": "Participants will receive 12 weekly sessions of Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure (COPE Therapy), plus intranasal Oxytocin.<br/>40-IU dose of Oxytocin self-administered 30 minutes prior to the start of each weekly COPE session.",
... | [
"PTSD",
"Alcohol Use Disorder"
] | [
"The Medical University of South Carolina"
] | [
"National Institute on Alcohol Abuse & Alcoholism"
] | [
[
{
"name": "缩宫素",
"lang": "CN"
},
{
"name": "Oxytocin",
"lang": "EN"
},
{
"name": "オキシトシン",
"lang": "JP"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "COPE+OT"
}
] |
NCT04999137 | [
{
"id_field": "org_study_id",
"id_value": [
"19-094"
]
},
{
"id_field": "acronym",
"id_value": [
"REVISTA-DOSE"
]
}
] | https://clinicaltrials.gov/study/NCT04999137 | Evaluation of Safety and Dosing of a Vitamin C Bundle for Sepsis Treatment in Africa | Open-label phase 2a Randomized Controlled Trial (RCT) assessing the pharmacokinetics of two different doses of intravenous vitamin C given alongside vitamin B1 in adult medical patients with sepsis and hypotension. | Evaluation of Pharmacokinetics, Safety and Feasibility for Administration of Two Doses of Intravenous Vitamin C Combined With Vitamin B1 for the Management of Adult Patients Admitted With Sepsis to Kiruddu National Referral Hospital | [
{
"description": "Vitamin C (ascor), infused intravenously in 50 mls sodium chloride (NaCl) over 30 minutes every 6 hours for 16 doses",
"name": "Vitamin C",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"other_name": [
"Ascor",
"Ascorbate"
],
"type": "Drug"
},
{
... | [
{
"design_group_description": "intravenous vitamin C (1.5 grams) every 6 hours for 16 doses in combination with intravenous vitamin B1 (200 mg) every 12 hours",
"design_group_title": "Intravenous vitamin C 1.5g + intravenous vitamin B1",
"design_group_type": "Experimental",
"design_group_type_normal... | [
"Sepsis",
"Septic Shock",
"HIV"
] | [
"Liverpool School of Tropical Medicine"
] | [
"University of Copenhagen",
"The University of Liverpool"
] | [
[
{
"name": "盐酸硫胺素",
"lang": "CN"
},
{
"name": "Thiamine Hydrochloride",
"lang": "EN"
},
{
"name": "チアミン塩化物塩酸塩",
"lang": "JP"
}
],
[
{
"name": "维生素C",
"lang": "CN"
},
{
"name": "Ascorbic Acid",
"lang": "EN"
},
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "REVISTA-DOSE"
}
] |
NCT00166543 | [
{
"id_field": "org_study_id",
"id_value": [
"2216-03"
]
},
{
"id_field": "secondary_id",
"id_value": [
"TAS108-0004"
]
},
{
"id_field": "nct_alias",
"id_value": [
"NCT00687557"
]
}
] | https://clinicaltrials.gov/study/NCT00166543 | Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer | This study is being done to find out how safe TAS-108 is and how well TAS-108 works on recurrent or recurrent inoperable breast cancer. | A Phase II, Randomized, Double-Blinded Efficacy and Safety Study of Three Doses of TAS-108 Administered Orally in Postmenopausal Patients With Locally Advanced or Locally Recurrent Inoperable or Progressive Metastatic Breast Cancer Following Standard First-Line Endocrine Therapy | [
{
"name": "TAS-108",
"normalized_type": "3d1aa88261d64c038413723970f2b58b",
"type": "Drug"
}
] | [
{
"design_group_title": "TAS-108 40 mg",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_name": "TAS-108",
"intervention_type": "Drug",
"normalized_intervention_type": "3d1aa88... | [
"Breast Cancer"
] | [
"SRI International"
] | [
"Taiho Pharmaceutical Co., Ltd."
] | [
[
{
"name": "SR-16234",
"lang": "EN"
}
]
] | null |
NCT04714619 | [
{
"id_field": "org_study_id",
"id_value": [
"MedOPP319"
]
},
{
"id_field": "acronym",
"id_value": [
"CAILA"
]
}
] | https://clinicaltrials.gov/study/NCT04714619 | CB-103 Plus NSAI In Luminal Advanced Breast Cancer | Multicenter, single-arm, open label, phase II clinical trial with safety run-in to evaluate the safety, tolerability, pharmacokinetics and efficacy of CB-103 in combination with a non-steroidal aromatase inhibitor (NSAI), anastrozole or letrozole, in Hormone Receptor-positive and Human Epidermal Growth Factor Receptor ... | CB-103 Plus NSAI In Luminal Advanced Breast Cancer: CAILA Study | [
{
"description": "Patients will receive CB-103 capsules orally (QD) in combination with NSAI therapy (letrozole or anastrozole, continuing prior therapy) also orally once daily, and based on a 28-day treatment cycle.<br/>A run-in phase for safety and tolerability of CB-103 in combination with anastrozole or let... | [
{
"design_group_description": "Hormone Receptor (HR)-positive and HER2-negative advanced breast cancer, including metastatic (ABC).Approximately 80 patients",
"design_group_title": "CB-103 + NSAI therapy",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33... | [
"Advanced Breast Cancer"
] | [
"Medica Scientia Innovation Research SL"
] | [
"Cellestia Biotech AG"
] | [
[
{
"name": "Limantrafin",
"lang": "EN"
}
]
] | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
}
],
"value": "CAILA"
}
] |
NCT03542266 | [
{
"id_field": "org_study_id",
"id_value": [
"1711018777"
]
}
] | https://clinicaltrials.gov/study/NCT03542266 | CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma | This is a phase II, multi-center study to determine the efficacy and safety of first-line CC-486 plus CHOP in patients with PTCL who have received no prior systemic therapy. The study has a sample size of 20, and follows two-stage minimax design for primary efficacy analysis. | A Multi-center Phase II Study of CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma | [
{
"description": "CC-486 at 300 mg once daily is to be administered Cycle 1, Day -6 to 0 and Cycles 1 to 5, Day 8 to 21. Antiemetic prophylaxis is recommended before dosing. All efforts should be made to administer CC-486 on all scheduled days of the Cycle 1 priming dosing (7 days, Cycle 1 Day -6 to Cycle 1 Day... | [
{
"design_group_description": "CC486 +CHOP",
"design_group_title": "CC486 +CHOP",
"design_group_type": "Experimental",
"design_group_type_normalized_id": "704b5561562b354480f33f22cf61c5f5",
"intervention": [
{
"intervention_description": "CC-486 at 300 mg once daily is to be admini... | [
"Previously Untreated Peripheral T-cell Lymphoma"
] | [
"Weill Medical College of Cornell University"
] | [
"Celgene Corp."
] | [
[
{
"name": "环磷酰胺",
"lang": "CN"
},
{
"name": "Cyclophosphamide",
"lang": "EN"
},
{
"name": "シクロホスファミド水和物",
"lang": "JP"
}
],
[
{
"name": "泼尼松",
"lang": "CN"
},
{
"name": "Prednisone",
"lang": "EN"
}
],
[
... | null |
NCT00534469 | [
{
"id_field": "org_study_id",
"id_value": [
"99040"
]
},
{
"id_field": "secondary_id",
"id_type": "U.S. NIH Grant/Contract",
"id_value": [
"P30CA033572"
]
},
{
"id_field": "secondary_id",
"id_value": [
"CHNMC-99040"
]
},
{
"id_domain": "NCI P... | https://clinicaltrials.gov/study/NCT00534469 | Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R | RATIONALE: Giving chemotherapy before an autologous stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. After treatment, stem cells are collected from the patient's blood and/or bone marrow and stored. More chemotherapy and radiation therapy is given to prepare the bone... | Autologous Bone Marrow Transplantation for Non-M3 Acute Myeloid Leukemia (AML) in First Remission in Patients </=60 Years of Age Using Busulfan/Fractionated Total Body Irradiation (FTBI) and VP16 as the Preparative Regimen | [
{
"name": "aldesleukin",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"Proleukin"
],
"type": "Biological"
},
{
"name": "filgrastim",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"Neupogen"
],
"type": "Biologi... | [
{
"design_group_description": "This study was designed as a single-arm study.<br/>Strata were:<br/>HD ARA-C w/ Idarubicin, CR<6 months N = 24 patients. HD ARA-C w/ Idarubicin, CR>6 months N=1. HD ARA-C consolidation, CR<6 months N=5. HD ARA-C consolidation, CR>6 months N= 0.",
"design_group_title": "HD ARA-... | [
"Leukemia"
] | [
"City of Hope National Medical Center"
] | [
"National Cancer Institute"
] | [
[
{
"name": "依托泊苷",
"lang": "CN"
},
{
"name": "Etoposide",
"lang": "EN"
},
{
"name": "エトポシド",
"lang": "JP"
}
],
[
{
"name": "白消安",
"lang": "CN"
},
{
"name": "Busulfan",
"lang": "EN"
},
{
"name": "ブスルファン... | null |
NCT03797326 | [
{
"id_field": "org_study_id",
"id_value": [
"7902-005"
]
},
{
"id_domain": "MSD Protocol Number",
"id_field": "secondary_id",
"id_type": "Other Identifier",
"id_value": [
"MK-7902-005"
]
},
{
"id_domain": "Eisai Protocol Number",
"id_field": "secondary_id"... | https://clinicaltrials.gov/study/NCT03797326 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | The purpose of this study is to determine the safety and efficacy of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080/MK-7902) in participants with triple negative breast cancer (TNBC), ovarian cancer, gastric cancer, colorectal cancer (CRC), glioblastoma (GBM), biliary tract cancers (BTC), or pan... | A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects With Selected Solid Tumors (LEAP-005) | [
{
"description": "Administered as an IV infusion on Day 1 Q3W.",
"name": "Pembrolizumab",
"normalized_type": "30faef638ae74cc7957c665e1b5ed8af",
"other_name": [
"Keytruda®",
"MK-3475"
],
"type": "Biological"
},
{
"description": "Administered orally once a day during each ... | [
{
"design_group_description": "Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) plus lenvatinib 20 mg via oral capsule once a day (QD). Pembrolizumab will be administered for up to 35 cycles (up to 2 years). Lenvatinib will be administered until progres... | [
"Advanced Solid Tumors",
"Triple Negative Breast Cancer",
"Ovarian Cancer",
"Gastric Cancer",
"Colorectal Cancer",
"Glioblastoma",
"Biliary Tract Cancers",
"Pancreatic Cancer"
] | [
"Merck Sharp & Dohme Corp."
] | [
"Eisai, Inc."
] | [
[
{
"name": "帕博利珠单抗",
"lang": "CN"
},
{
"name": "Pembrolizumab",
"lang": "EN"
},
{
"name": "ペムブロリズマブ（遺伝子組換え）",
"lang": "JP"
}
],
[
{
"name": "甲磺酸仑伐替尼",
"lang": "CN"
},
{
"name": "Lenvatinib mesylate",
"lang": "EN"
... | [
{
"identifier_source": [
{
"source": "CLINICAL_TRIAL_AUTO",
"status": "ACTIVE"
},
{
"code": "290a28a8e594ea303aaaa39dae3d0852",
"source": "CT_RESULT_AUTO",
"status": "ACTIVE"
},
{
"code": "34aa525e5d32eee22282a3a5eee3e222",
"s... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.